<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2507233928
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OFEV 100 mg Soft Capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NINTEDANIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        5370.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CATALENT GERMANY EBERBACH GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CATALENT GERMANY EBERBACH GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BOEHRINGER INGELHEIM
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE31
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ofev contains the active substance nintedanib, a medicine belonging to the class of so-called tyrosine<br />kinase inhibitors, and it is used for the treatment of idiopathic pulmonary fibrosis (IPF), other chronic<br />fibrosing interstitial lung diseases (ILDs) with a progressive phenotype and systemic sclerosis<br />associated interstitial lung disease (SSc-ILD) in adults.<br />Idiopathic pulmonary fibrosis (IPF)<br />IPF is a condition in which the tissue in your lungs becomes thickened, stiff and scarred over time. As<br />a result, scarring reduces the ability to transfer oxygen from the lungs into the bloodstream and it<br />becomes difficult to breathe deeply. Ofev helps to reduce scarring and stiffening of the lungs.<br />Other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype<br />Besides IPF, there are other conditions in which the tissue in your lungs becomes thickened, stiff, and<br />scarred over time (lung fibrosis) and keeps worsening (progressive phenotype). Examples of these<br />conditions are hypersensitivity pneumonitis, autoimmune ILDs (e.g. rheumatoid arthritis associated<br />ILD), idiopathic nonspecific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia,<br />and other ILDs. Ofev helps to reduce further scarring and stiffening of the lungs.<br />Systemic sclerosis associated interstitial lung disease (SSc-ILD)<br />Systemic sclerosis (SSc), also known as scleroderma, is a rare chronic autoimmune disease that affects<br />connective tissue in many parts of the body. SSc causes fibrosis (scarring and stiffening) of the skin<br />and other internal organs such as the lungs. When the lungs are affected by fibrosis, it is called<br />interstitial lung disease (ILD), and so the condition is called SSc-ILD. Fibrosis in the lungs reduces the<br />ability to transfer oxygen into the bloodstream, and breathing capacity is reduced. Ofev helps to reduce<br />further scarring and stiffening of the lungs.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Ofev<br />- if you are pregnant,<br />- if you are allergic to nintedanib, peanut or soya, or any of the other ingredients of this medicine<br />(listed in section 6).<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Ofev,<br />- if you have or have had liver problems,<br />- if you have or have had problems with your kidneys, or if an increased amount of protein has been<br />detected in your urine,<br />- if you have or have had bleeding problems,<br />- if you take blood-thinning medicines (such as warfarin, phenprocoumon or heparin) to prevent<br />blood clotting,<br />- if you take pirfenidone as this may increase the risk of having diarrhoea, nausea, vomiting and liver<br />problems,<br />- if you have or have had problems with your heart (for example a heart attack),<br />- if you have recently had surgery. Nintedanib may affect the way your wounds heal. Therefore, your<br />treatment with Ofev will usually be stopped for a while if you are having a surgery. Your doctor<br />will decide when to resume your treatment with this medicine.<br />- if you have high blood pressure,<br />- if you have abnormally high blood pressure in the blood vessels of the lungs (pulmonary<br />hypertension),<br />- if you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear<br />in a blood vessel wall.<br />Based on this information your doctor may do some blood tests, for example to check your liver<br />function. Your doctor will discuss the results of these tests with you and decide whether you may<br />receive Ofev.<br />Inform your doctor immediately while taking this medicine,<br />- if you get diarrhoea. Treating diarrhoea early is important (see section 4);<br />- if you vomit or feel sick (nausea);<br />- if you have unexplained symptoms such as yellowing of your skin or the white part of your eyes<br />(jaundice), dark or brown (tea coloured) urine, pain on the upper right side of your stomach area<br />(abdomen), bleeding or bruising more easily than normal, or feeling tired. This could be symptoms<br />of serious liver problems;<br />- if you have severe pain in your stomach, fever, chills, sickness, vomiting, or abdominal rigidity or<br />bloating, as these could be symptoms of a hole in the wall of your gut (&lsquo;gastrointestinal<br />perforation&rsquo;). Also, tell your doctor if you had peptic ulcers or diverticular disease in the past, or<br />are concomitantly treated with anti-inflammatory drugs (NSAIDs) (used to treat pain relief and<br />swelling) or steroids (used for inflammation and allergies), as this may increase this risk;<br />- if you have a combination of severe pain or cramping in your stomach, red blood in your stool or<br />diarrhea as these could be symptoms of a bowel inflammation from inadequate blood supply;<br />- if you have pain, swelling, reddening, warmth of a limb as this could be symptoms of a blood clot<br />in one of your veins (a type of blood vessel);<br />- if you have chest pressure or pain, typically on the left side of the body, pain in the neck, jaw,<br />shoulder or arm, a fast heartbeat, shortness of breath, nausea, vomiting, as this could be symptoms<br />of a heart attack;<br />- if you have any major bleeding.<br />- if you experience bruising, bleeding, fever, fatigue and confusion. This may be a sign of damage to<br />blood vessels known as thrombotic microangiopathy (TMA).<br />Children and adolescents<br />Ofev should not be taken by children and adolescents under 18 years of age.<br />Other medicines and Ofev<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines, including herbal medicines and medicines obtained without a prescription.<br />Ofev can interact with certain other medicines. The following medicines are examples that may<br />increase the levels of nintedanib in your blood, and hence may increase the risk for side effects (see<br />section 4):<br />- a medicine used to treat fungal infections (ketoconazole)<br />- a medicine used to treat bacterial infections (erythromycin)<br />- a medicine that affects your immune system (cyclosporine)<br />The following medicines are examples that may lower the levels of nintedanib in your blood and thus<br />may reduce the effectiveness of Ofev:<br />- an antibiotic used to treat tuberculosis (rifampicin)<br />- medicines to treat seizures (carbamazepine, phenytoin)<br />- a herbal medicine to treat depression (St. John&rsquo;s Wort)<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask<br />your doctor or pharmacist for advice before taking this medicine.<br />Pregnancy<br />Do not take this medicine during pregnancy, as it can harm your unborn baby and cause birth defects.<br />You must have a pregnancy test done to ensure you are not pregnant before starting treatment with<br />Ofev. Please talk to your doctor.<br />Contraception<br />- Women who can become pregnant must use a highly effective method of birth control to prevent<br />pregnancy when they start taking Ofev, while they are taking Ofev and for at least 3 months after<br />stopping treatment.<br />- You should discuss the most appropriate methods of contraception for you with your doctor.<br />- Vomiting and/or diarrhoea or other gastrointestinal conditions can affect the absorption of oral<br />hormonal contraceptives, such as birth control pills, and may reduce their effectiveness.Therefore,<br />if experiencing these, talk to your doctor to discuss an alternative more appropriate method of<br />contraception.<br />- Tell your doctor or pharmacist immediately if you become pregnant or think you may be pregnant<br />during treatment with Ofev.<br />Breast-feeding<br />Do not breast-feed during the treatment with Ofev since there may be a risk of harm to the breast-fed<br />child.<br />Driving and using machines<br />Ofev may have minor influence on your ability to drive and use machines. You should not drive or use<br />machines if you feel sick.<br />Ofev contains soya lecithin<br />If you are allergic to soya or peanut, do not take this medicine (see section 2).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor<br />or pharmacist if you are not sure.<br />The recommended dose is one capsule of 100 mg twice daily (a total of 200 mg per day).<br />The recommended dose is one capsule of 150 mg twice daily (a total of 300 mg per day).<br />Take the capsules twice daily approximately 12 hours apart at about the same time every day, for<br />example one capsule in the morning and one capsule in the evening. This ensures that a steady<br />amount of nintedanib is maintained in your blood stream. Swallow the whole capsules with water<br />and do not<br />chew the capsules. It is recommended that you take the capsules with food, i.e. during or immediately<br />before or after a meal. Do not open or crush the capsule (see section 5).<br />Do not take more than the recommended dose of two Ofev 100 mg / 150 mg capsules per day.<br />If you do not tolerate the recommended dose of two Ofev 100 mg / 150 mg capsules per day (see<br />possible side effects in section 4) your doctor may advise you to stop taking this medicine. Do not<br />reduce the dose or stop the treatment by yourself without consulting your doctor first.<br />If you take more Ofev than you should<br />Contact your doctor or pharmacist immediately.<br />If you forget to take Ofev<br />Do not take two capsules together if you have forgotten to take your earlier dose. You should take<br />your next 100 mg / 150 mg dose of Ofev as planned at the next scheduled time recommended by your<br />doctor or pharmacist.<br />If you stop taking Ofev<br />Do not stop taking Ofev without consulting your doctor first. It is important to take this medicine every<br />day, as long as your doctor prescribes it for you.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />You need to pay special attention if you get the following side effects during treatment with Ofev:<br />Diarrhoea (very common, may affect more than 1 in 10 people):<br />Diarrhoea may lead to dehydration: a loss of fluid and important salts (electrolytes, such as sodium or<br />potassium) from your body. At the first signs of diarrhoea drink plenty of fluids and contact your<br />doctor immediately. Start appropriate anti-diarrhoeal treatment, e.g. with loperamide, as soon as<br />possible.<br />The following other side effects were observed during treatment with this medicine.<br />Talk to your doctor if you get any side effects.<br />Idiopathic pulmonary fibrosis (IPF)<br />Very common side effects (may affect more than 1 in 10 people)<br />- Feeling sick (nausea)<br />- Pain in the lower body (abdomen)<br />- Abnormal liver test results<br />Common side effects (may affect up to 1 in 10 people)<br />- Vomiting<br />- Loss of appetite<br />- Weight loss<br />- Bleeding<br />- Rash<br />- Headache<br />Uncommon side effects (may affect up to 1 in 100 people)<br />- Pancreatitis<br />- Inflammation of the large bowel<br />- Serious liver problems<br />- Low platelet count (thrombocytopenia)<br />- High blood pressure (hypertension)<br />- Jaundice, that is a yellow colour to the skin and whites of the eyes due to high levels of bilirubin<br />- Itching<br />- Heart attack<br />- Hair loss (alopecia)<br />- Increased amount of protein in your urine (proteinuria)<br />Not known (cannot be estimated from the available data)<br />- Renal failure<br />- An enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (aneurysms<br />and artery dissections)<br />Other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype<br />Very common side effects (may affect more than 1 in 10 people)<br />- Feeling sick (nausea)<br />- Vomiting<br />- Loss of appetite<br />- Pain in the lower body (abdomen)<br />- Abnormal liver test results<br />Common side effects (may affect up to 1 in 10 people)<br />- Weight loss<br />- High blood pressure (hypertension)<br />- Bleeding<br />- Serious liver problems<br />- Rash<br />- Headache<br />Uncommon side effects (may affect up to 1 in 100 people)<br />- Pancreatitis<br />- Inflammation of the large bowel<br />- Low platelet count (thrombocytopenia)<br />- Jaundice, that is a yellow colour to the skin and whites of the eyes due to high levels of bilirubin<br />- Itching<br />- Heart attack<br />- Hair loss (alopecia)<br />- Increased amount of protein in your urine (proteinuria)<br />Not known (cannot be estimated from the available data)<br />- Renal failure<br />- An enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (aneurysms<br />and artery dissections)<br />Systemic sclerosis associated interstitial lung disease (SSc-ILD)<br />Very common side effects (may affect more than 1 in 10 people)<br />- Feeling sick (nausea)<br />- Vomiting<br />- Pain in the lower body (abdomen)<br />- Abnormal liver test results<br />Common side effects (may affect up to 1 in 10 people)<br />- Bleeding<br />- High blood pressure (hypertension)<br />- Loss of appetite<br />- Weight loss<br />- Headache<br />Uncommon side effects (may affect up to 1 in 100 people)<br />- Inflammation of the large bowel<br />- Serious liver problems<br />- Renal failure<br />- Low platelet count (thrombocytopenia)<br />- Rash<br />- Itching<br />Not known (cannot be estimated from the available data)<br />- Heart attack<br />- Pancreatitis<br />- Jaundice, that is a yellow colour to the skin and whites of the eyes due to high levels of bilirubin<br />- An enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (aneurysms<br />and artery dissections)<br />- Hair loss (alopecia)<br />- Increased amount of protein in your urine (proteinuria)<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects<br />not listed in this leaflet. You can also report side effects directly via the national reporting system. By<br />reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton and the blister. The expiry<br />date refers to the last day of that month.<br />Store in a refrigerator (2 - 8&deg;C).<br />Store in the original package in order to protect from moisture.<br />Do not use this medicine if you notice that the blister containing the capsules is opened or a capsule is<br />broken.<br />If you are in contact with the content of the capsule, wash off your hands immediately with plenty of<br />water (see section 3).<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is nintedanib. Each capsule contains 100 mg / 150 mg nintedanib (as esilate).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>Capsule fill:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Triglycerides, medium-chain, hard fat, soya lecithin (E322) (see section 2)</p><p>Capsule shell:&nbsp;&nbsp;&nbsp;&nbsp; Gelatin, glycerol (85%), titanium dioxide (E171), iron oxide red (E172), iron oxide yellow (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ofev 100 mg capsules are peach-coloured, opaque, oblong soft-gelatin capsules (approx. 16 x 6 mm) marked on one side with the Boehringer Ingelheim company symbol and the figure “100”.
Ofev 150 mg capsules are brown-coloured, opaque, oblong soft-gelatin capsules (approx. 18 x 7 mm) marked on one side with the Boehringer Ingelheim company symbol and the figure “150”.
Two pack-sizes of Ofev 100 mg / 150 mg capsules are available:
-	30 x 1 soft capsules in aluminium/aluminium perforated unit dose blisters
-	60 x 1 soft capsules in aluminium/aluminium perforated unit dose blisters Not all pack-sizes or strengths may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Boehringer Ingelheim International GmbH<br />Binger Strasse 173<br />55216 Ingelheim am Rhein<br />Germany</p><p><br />Manufacturer<br />Boehringer Ingelheim Pharma GmbH &amp; Co. KG<br />Binger Strasse 173<br />55216 Ingelheim am Rhein<br />Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing<br />Authorisation Holder:<br />Kingdom of Saudi Arabia (Scientific Office)<br />Riyadh.<br />Tel: +966-11-5116504<br />Fax: +966-11-5116545</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Jul 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار أوفيف على المادة الفعَّالة نينتدانيب، وهو دواء ينتمي إلى فئة تُدعى مثبطات إنزيم التيروزين كيناز، ويُستخدم لعلاج التَلَيُّف الرِئَوِي مجهول السبب وغيرهما من أمراض الرئة الخلالية المُلَيِّفة المزمنة ذات النمط الظاهري المُترقي و مرض الرئة الخلالي المرتبط بالتَصَلُّب الجهازي في البالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التَلَيُّف الرِئَوِي مجهول السبب</u></p><p dir="RTL">التليُّف الرئوي مجهول السبب هو حالة تصبح فيها أنسجة الرئة لديك سميكة وصلبة ومتندبة مع مرور الوقت. نتيجة لذلك، يقلل التندُّب القدرة على نقل الأكسجين من الرئتين إلى مجرى الدم ويصبح التنفس بعمق أمرًا صعبًا. يساعد عقار أوفيف على تقليل تندُّب وتصلُب الرئتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>أمراض الرئة الخلالية المُلَيِّفة المزمنة الأخرى ذات النمط الظاهري المُترقي</u></p><p dir="RTL">بجانب التليُّف الرئوي مجهول السبب، هناك حالات أخرى تصبح فيها أنسجة الرئة لديك سميكة وصلبة ومتندبة مع مرور الوقت (التليف الرئوي) وتستمر في التدهور (النمط الظاهري المترقي). تشتمل الأمثلة على هذه الحالات الالتِهاب الرِئَوِي بفَرْطِ الحساسية، أمراض الرئة الخلالية الناجمة عن المناعة الذاتية (على سبيل المثال: مرض الرئة الخلالي المرتبط بالتهاب المفاصل الروماتويدي)، الالتهاب الرئوي الخلالي غير المُحدد مجهول السبب، الالتهاب الرئوي الخلالي مجهول السبب غير القابل للتصنيف وأمراض الرئة الخلالية الأخرى. يساعد عقار أوفيف على تقليل المزيد من التندُّب والتصلُب للرئتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مرض الرئة الخلالي المرتبط بالتَصَلُّب الجهازي</u></p><p dir="RTL">التَصَلُّب الجهازي، يُعرف أيضًا بتصلب الجلد، هو أحد أمراض المناعة الذاتية المزمنة النادرة التي تصيب الأنسجة الضامة بعدة أجزاء من الجسم. يتسبب التَصَلُّب الجهازي في تَلَيُّف (تندُّب وتصلب) الجلد وغيره من الأعضاء الداخلية مثل الرئتين. حينما تُصاب الرئتان بالتَلَيُّف، يُسمى ذلك بمرض الرئة الخلالي ومن ثم تُدعى الحالة مرض الرئة الخلالي المرتبط بالتَصَلُّب الجهازي. يحد تَلَيُّف الرئتين من القدرة على نقل الأكسجين إلى مجرى الدم، فتنخفض القدرة على التنفس. يساعد عقار أوفيف على تقليل المزيد من التندُّب والتصلُب للرئتين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول عقار أوفيف في الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتي حامل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه نينتدانيب أو الفول السوداني أو فول الصويا أو تجاه أيٍّ من المكونات الأخرى بهذا الدواء (المدرجة في القسم: 6).</p><p dir="RTL">&nbsp;</p><p>تحذيرات واحتياطات</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي الخاص بك قبل تناوُل عقار أوفيف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو قد عانيت من قبل من مشاكل في الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو قد عانيت من قبل من مشاكل في الكلى أو تم الكشف عن زيادة كمية البروتين في البول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو قد عانيت من قبل من مشاكل نزفية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تناولت أدوية لتسييل الدم (مثل: وارفارين، فينوبروكومون أو هيبارين) لمنع تجلط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول بيرفنيدون لأن هذا قد يزيد من خطر الإصابة بالإسهال والغثيان والقيء ومشاكل الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو قد عانيت من قبل من مشاكل في القلب (على سبيل المثال: نوبة قلبية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت مؤخرًا للجراحة. قد يؤثر نينتدانيب على طريقة التئام الجروح لديك. من ثم سيتم عادة وقف علاجك بعقار أوفيف لفترة من الوقت إذا كنت ستخضع للجراحة. سيقرر طبيبك متى سيتم استئناف علاجك بهذا الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع ضغط الدَّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع غير طبيعي بضغط الدَّم في الأوعية الدموية الخاصة بالرئتين (ارتفاع ضغط الدم الرئوي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني أو قد عانيت من قبل من تمدد الأوعية الدموية (تضخم وضعف جدار الأوعية الدموية) أو تمزق في جدار الأوعية الدموية</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">بناءً على هذه المعلومات، قد يُجري طبيبك بعض اختبارات الدم، على سبيل المثال لفحص وظائف الكبد لديك. سيناقش طبيبك نتائج هذه الاختبارات معك وسيقرر ما إذا كان من الممكن أن تتلقى عقار أوفيف أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ طبيبك فورًا أثناء تناوُل هذا الدَّواء في الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت بإسهال. يُعدّ العلاج المبكر للإسهال أمرًا هامًّا (انظر قسم: 4).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تقيأت أو شعرت بالإعياء (الغثيان).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أعراض غير مبررة مثل اصفرار الجلد أو الجزء الأبيض من عينيك (يرقان)، بول داكن أو بني (لون الشاي)، ألم في الجانب الأيمن العلوي من منطقة المعدة (البطن)، الإصابة بنزيف أو كدمات بسهولة أكبر من المعتاد أو الشعور بالتعب. قد تكون هذه أعراض لحدوث مشاكل خطيرة في الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ألم شديد في المعدة، أو حمى، أو قشعريرة، أو إعياء، أو قيء أو تصلب في البطن أو انتفاخ؛ إذ قد تكون هذه أعراض لحدوث ثقب في جدار الأمعاء (&quot;انثقاب في الجهاز الهضمي&quot;). أخبر طبيبك أيضًا، إذا كنت قد عانيت من قرح هضمية أو مرض رتجي في الماضي، أو يتم علاجك بشكل متزامن بالأدوية المضادة للالتهاب (مضادات الالتهاب غير الستيرويدية) (التي تستخدم لتخفيف الألم والتورم) أو الستيرويدات (التي تُستخدم لعلاج الالتهاب والحساسية)؛ إذ قد يُؤدي ذلك إلى زيادة هذا الخطر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مزيج من الألم الشديد أو التقلصات في معدتك ، أو دم أحمر في البراز أو الإسهال ، فقد تكون هذه أعراض التهاب الأمعاء بسبب نقص وصول الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ألم أو تورم أو احمرار أو إحساس بالدفء في أحد الأطراف، إذ قد تكون هذه أعراض لتكوّن جلطة دموية في أحد الأوردة لديك (أحد أنواع الأوعية الدموية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت من ضغط أو ألم بالصدر، عادةً على الجانب الأيسر من الجسم، ألم في الرقبة أو الفك أو الكتف أو الذراع، تسارع ضربات القلب، ضيق في التنفس، غثيان، قيء، إذ قد تكون هذه أعراض الإصابة بنوبة قلبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أيِّ نزيف بشكل كبير.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من كدمات ونزيف وحمى وإرهاق و تشويش. قد تكون هذه علامة على تلف الأوعية الدموية المعروفة باسم اعتلال الأوعية الدقيقة الخثاري</p><p dir="RTL">&nbsp;</p><p>الأطفال والمراهقون</p><p dir="RTL">يُحظر تناوُل الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا لعقار أوفيف.</p><p dir="RTL">&nbsp;</p><p>تناوُل عقار أوفيف مع أدوية أخرى</p><p dir="RTL">أخبر طبيبك أو الصيدلي الخاص بك إذا كُنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى، بما في ذلك الأدوية العشبية والأدوية التي يتم الحصول عليها دون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتداخل عقار أوفيف مع بعض الأدوية الأخرى. الأدوية التالية أمثلة على الأدوية التي قد ترفع مستويات نينتدانيب لديك في الدم، ومن ثم قد تزيد من خطر الإصابة بالآثار الجانبية (انظر قسم: 4):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء المُستخدم لعلاج العدوى الفطرية (كيتوكونازول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء المُستخدم لعلاج العدوى البكتيرية (إريثروميسين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء الذي يؤثر على جهازك المناعي (سيكلوسبورين)</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأدوية التالية أمثلة على الأدوية التي قد تخفض مستويات نينتدانيب لديك في الدم، ومن ثم قد تقلل من فعَّالية عقار أوفيف:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضاد الحيوي المُتسخدم لعلاج السُّل (ريفامبيسين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستخدم لعلاج النوبات التشنجية (كَرْبامازِيبين، فينيتوين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء العشبي الذي يُستخدم لعلاج الاكتئاب (نبتة سانت جونز)</p><p>&nbsp;</p><p>الحمل والرضاعة الطبيعية</p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لذلك، فاستشيري طبيبك أو الصيدلي الخاص بك قبل تناوُل هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">لا تتناولي هذا الدواء أثناء الحمل، إذ إنه قد يضر بجنينكِ ويسبب له عيوب خلقية.</p><p dir="RTL">يجب إجراء اختبار الحمل للتأكد من أنك لست حاملاً قبل بدء العلاج بـعقار أوفيف. من فضلك تحدث مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>موانع الحمل</u></p><p dir="RTL">يجب على السيدات اللاتي من الممكن أن يصبحن حوامل استخدام وسائل منع الحمل عالية الفعالية لمنع الحمل عند البدأ باستخدام عقار أوفيف، أثناء تناوُل عقار أوفيف ولمدة 3 أشهر على الأقل بعد وقف العلاج.</p><p dir="RTL">&nbsp;يجب عليكِ مناقشة وسائل منع الحمل الأنسب لكِ مع طبيبكِ.</p><p dir="RTL">يمكن أن يؤثر القيء و / أو الإسهال أو أمراض الجهاز الهضمي الأخرى على امتصاص موانع الحمل الهرمونية الفموية ، مثل حبوب منع الحمل ، وقد تقلل من فعاليتها ، لذلك ، إذا كنت تعاني من هذه الأعراض ، تحدث مع طبيبك لمناقشة طريقة بديلة أكثر ملاءمة لمنع الحمل .</p><p dir="RTL">أخبري طبيبكِ أو الصيدلي الخاص بكِ على الفور إذا أصبحتِ حاملًا أو تعتقدين أنك حامل أثناء العلاج بعقار أوفيف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">لا تمارسي الرضاعة الطبيعية أثناء العلاج بعقار أوفيف؛ إذ قد يكون هناك خطرُ لحدوث ضرر لطفلِك الرضيع.</p><p dir="RTL">&nbsp;</p><p>القيادة واستخدام الآلات</p><p dir="RTL">قد يكون لعقار أوفيف تأثير طفيف على القدرة على القيادة واستخدام الآلات. يجب عليك تجنُّب القيادة أو استخدام الآلات إذا شعرت بإعياء.</p><p dir="RTL">&nbsp;</p><p>يحتوي عقار أوفيف على ليسيثين الصويا</p><p dir="RTL">إذا كنت تعاني من الحساسية تجاه فول الصويا أو الفول السوداني، فلا تتناول هذا الدواء (انظر قسم: 2).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تَناوَل دائمًا هذا الدَّواء بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية التناوُل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي كبسولة واحدة 100 مجم مرتين يوميًّا (200 مجم يوميًّا إجمالًا).</p><p dir="RTL">الجرعة الموصى بها هي كبسولة واحدة 150 مجم مرتين يوميًّا (300 مجم يوميًّا إجمالًا).</p><p dir="RTL">&nbsp;باعد بين تناوُل الكبسولات بفاصل زمني تقريبي قدره 12 ساعة وتناولها في الوقت نفسه تقريبًا كل يوم، على سبيل المثال كبسولة واحدة صباحًا وكبسولة واحدة مساءً. يضمن هذا بقاء كمية ثابتة من نينتدانيب لديك في مجرى الدم. ابتلع الكبسولات كاملة مع الماء ولا تمضغها أو تسحقها. يوصى بتناوُل الكبسولات مع الطعام، أي أثناء الوجبات أو قبلها أو بعدها مباشرة لا تقم بفتح أو كسر الكبسولة (انظر للقسم 5).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول أكثر من الجرعة الموصى بها التي تبلغ كبسولتين من عقار أوفيف 100 مجم/ 150 مجم يوميًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن تحتمل الجرعة الموصى بها التي تبلغ كبسولتين من عقار أوفيف 100 مجم/150 مجم يوميًّا (انظر الآثار الجانبية المحتملة في القسم: &quot;4&quot;)، فقد ينصحك طبيبك بإقاف العلاج. لا تخفض الجرعة أو توقف العلاج من تلقاء نفسك دون استشارة طبيبك أولًا.</p><p dir="RTL">&nbsp;</p><p>إذا تناولت كمية من عقار أوفيف أكثر مما يجب</p><p dir="RTL">يُرجى الاتصال بطبيبك أو الصيدلي الخاص بك على الفور.</p><p dir="RTL">&nbsp;</p><p>إذا أغفلت تناوُل عقار أوفيف</p><p dir="RTL">لا تتناول كبسولتين معًا إذا أغفلت تناوُل جرعتك السابقة. يجب عليك تناوُل جرعتك التالية البالغة 100 مجم/ 150 مجم من عقار أوفيف كما هو مُحدد في الموعد التالي المقرر الذي أوصى به طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p>إذا توقفت عن تناوُل عقار أوفيف</p><p dir="RTL">لا تتوقف عن تناوُل عقار أوفيف بدون استشارة طبيبك أولًا. من المهم تناوُل هذا الدَّواء كل يوم، طالما وصفه لك طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تتوخى حذرًا خاصًّا، إذا أصبت بأيٍّ من الآثار الجانبية التالية أثناء العلاج بعقار أوفيف:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إِسْهال </strong>(<em>شائع جدًّا</em> <em>قد يُؤثر على أكثر من شخص واحد من بين كل </em><em>10&nbsp;</em><em>أشخاص</em><em>):</em></p><p dir="RTL">قد يؤدي الإسهال إلى حدوث الجفاف: فقدان السوائل والأملاح الهامة (الاليكتروليتات مثل: الصوديوم أو البوتاسيوم) من جسمك. اشرب كمية كبيرة من السوائل عند ظهور أولى علامات الإصابة بالإسهال وتواصل مع طبيبك فورًا. ابدأ علاجًا مناسبًا مضادًّا للإسهال، على سبيل المثال: بعقار لوبيراميد في أقرب وقت ممكن.</p><p dir="RTL">&nbsp;</p><p>تم ملاحظة الآثار الجانبية الأخرى التالية أثناء العلاج بهذا الدواء.</p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك. <u>التَلَيُّف الرِئَوِي مجهول السبب</u></p><p dir="RTL"><em>الآثار الجانبية الشائعة جدًّا </em><em>(</em><em>قد تُؤثر على أكثر من شخص واحد من بين كل </em><em>10&nbsp;</em><em>أشخاص</em><em>)</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (الغثيان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الجزء السفلي من الجسم (البطن)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية في اختبارات الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الآثار الجانبية الشائعة </em><em>(</em><em>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </em><em>10&nbsp;</em><em>أشخاص</em><em>)</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الآثار الجانبية غير الشائعة </em><em>(</em><em>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </em><em>100 </em><em>شخص</em><em>)</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء الغليظة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل خطيرة في الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة تعداد الصفائح الدَّموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدَّم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرقان، وهو اصفرار لون الجلد وبياض العينين بسبب ارتفاع مستويات البيليروبين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر (الثعلبة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة كمية البروتين في البول</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>غير معروفة </em><em>(</em><em>لا يمكن تقديرها من واقع البيانات المتاحة</em><em>)</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكُلوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم وضعف جدار الأوعية الدموية أو تمزق في جدار الأوعية الدموية (تمدد الأوعية الدموية وتَسَلُّخ الشريان)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>أمراض الرئة الخلالية المُلَيِّفة المزمنة الأخرى ذات النمط الظاهري المُترقي</u></p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الآثار الجانبية الشائعة جدًّا </em><em>(</em><em>قد تُؤثر على أكثر من شخص واحد من بين كل </em><em>10&nbsp;</em><em>أشخاص</em><em>)</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (الغثيان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الجزء السفلي من الجسم (البطن)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية في اختبارات الكبد</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>الآثار الجانبية الشائعة </em><em>(</em><em>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </em><em>10&nbsp;</em><em>أشخاص</em><em>)</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدَّم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل خطيرة في الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الآثار الجانبية غير الشائعة </em><em>(</em><em>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </em><em>100 </em><em>شخص</em><em>)</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء الغليظة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة تعداد الصفائح الدَّموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرقان، وهو اصفرار لون الجلد وبياض العينين بسبب ارتفاع مستويات البيليروبين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر (الثعلبة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة كمية البروتين في البول</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>غير معروفة </em><em>(</em><em>لا يمكن تقديرها من واقع البيانات المتاحة</em><em>)</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكُلوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم وضعف جدار الأوعية الدموية أو تمزق في جدار الأوعية الدموية (تمدد الأوعية الدموية وتَسَلُّخ الشريان)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مرض الرئة الخلالي المرتبط بالتَصَلُّب الجهازي</u></p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الآثار الجانبية الشائعة جدًّا </em><em>(</em><em>قد تُؤثر على أكثر من شخص واحد من بين كل </em><em>10&nbsp;</em><em>أشخاص</em><em>)</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (الغثيان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الجزء السفلي من الجسم (البطن)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية في اختبارات الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الآثار الجانبية الشائعة </em><em>(</em><em>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </em><em>10&nbsp;</em><em>أشخاص</em><em>)</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدَّم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الآثار الجانبية غير الشائعة </em><em>(</em><em>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </em><em>100 </em><em>شخص</em><em>)</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء الغليظة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل خطيرة في الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكُلوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة تعداد الصفائح الدَّموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>غير معروفة </em><em>(</em><em>لا يمكن تقديرها من واقع البيانات المتاحة</em><em>)</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرقان، وهو اصفرار لون الجلد وبياض العينين بسبب ارتفاع مستويات البيليروبين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكُلوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم وضعف جدار الأوعية الدموية أو تمزق في جدار الأوعية الدموية (تمدد الأوعية الدموية وتَسَلُّخ الشريان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر (الثعلبة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة كمية البروتين في البول</p><p dir="RTL">&nbsp;</p><p>الإبلاغ عن الآثار الجانبية</p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك. يشمل ذلك أيَّ آثار جانبية مُحتملة غير مُدّرجة في هذه النَّشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية بشكل مباشر عبر نظام الإبلاغ الوطني</p><p dir="RTL">&nbsp;بالإبلاغ عن الآثار الجانبية، يُمكنك المساعدة في تقديم المزيد من المعلومات حول أمان هذا الدَّواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية والشريط. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم التخزين في الثلاجة في درجة حرارة من 2-8 درجة مئوية.</p><p dir="RTL">يُخزن في العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدَّواء إذا لاحظت أن الشريط الذي يحتوي على الكبسولات مفتوح أو أن إحدى الكبسولات مكسورة.</p><p dir="RTL">إذا لامست محتوى الكبسولة، اغسل يديك فوراً بكمية كبيرة من الماء (انظر القسم 3).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي نينتدانيب. تحتوي كل كبسولة على 100 مجم/ 150 مجم من نينتدانيب (في هيئة إسيلات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">محتوى الكبسولة:&nbsp;&nbsp;&nbsp;&nbsp; دهون ثلاثية متوسطة الحلقة، دهون صلبة، ليثيسين الصويا (E322) (انظر قسم: 2)</p><p dir="RTL">غلاف الكبسولة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جيلاتين، جليسيرول (85٪)، ثاني أكسيد التيتانيوم (E171)، أكسيد الحديد الأحمر (E172)، أكسيد الحديد الأصفر (E172)</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كبسولات عقار أوفيف 100 مجم هي كبسولات ذات لون خوخي، غير شفافة، مستطيلة الشكل ومصنوعة من الجيلاتين اللين، (مايقارب 16 x 6 ملم ) مع علامة على أحد جانبيها شعار شركة بوهرنجر إنجلهايم والرقم &quot;100&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كبسولات عقار أوفيف 150 مجم هي كبسولات ذات لون بني، غير شفافة، مستطيلة الشكل ومصنوعة من الجيلاتين اللين، (مايقارب 18 x 7 ملم ) مع علامة على أحد جانبيها شعار شركة بوهرينجر إنجلهايم والرقم &quot;150&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر حجمين من العبوات التي تحتوي على كبسولات عقار أوفيف 100 مجم/ 150 مجم وهما:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30 &times; 1 كبسولات لينة في شرائط مثقوبة مصنوعة من الألومنيوم/الألومنيوم للجرعة المفردة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 60 &times; 1 كبسولات لينة في شرائط مثقوبة مصنوعة من الألومنيوم/الألومنيوم للجرعة المفردة</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات و التراكيز.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التَّسويق</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">شركة بوهرنجر إنجلهايم العالمية المحدودة، 173 شارع بينجر</p><p dir="RTL">55216 إنجلهايم إيه إم راين، ألمانيا</p><p dir="RTL">&nbsp;</p><p>جهة التَّصنيع</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">بوهرنجر إنجلهايم فارما المحدودة وشركاؤها، شراكة محدودة 173 شارع بينجر</p><p dir="RTL">55216 إنجلهايم إيه إم راين، ألمانيا</p><p>&nbsp;</p><p dir="RTL">للحصول على أية معلومات حول هذا الدواء، يُرجى الاتصال بالمندوب المحلي لمالك حق التسويق:</p><p dir="RTL">&nbsp;</p><p dir="RTL">للحصول على أي معلومات بخصوص هذا الدواء يرجى التواصل مع الممثل المحلي (المكتب العلمي)</p><p dir="RTL">هاتف:+966-11-5116504</p><p dir="RTL">فاكس:+966-11-5116545</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ofev 100 mg soft capsules
 Ofev 150 mg soft capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ofev 100 mg soft capsules
One soft capsule contains 100 mg nintedanib (as esilate)
Excipient with known effect
Each 100 mg soft capsule contains 1.2 mg of soya lecithin.
Ofev 150 mg soft capsules
One soft capsule contains 150 mg nintedanib (as esilate)
Excipient with known effect
Each 150 mg soft capsule contains 1.8 mg of soya lecithin.
For the full list of excipients, see section 6.1.

Ofev 150 mg soft capsules
One soft capsule contains 150 mg nintedanib (as esilate)
Excipient with known effect
Each 150 mg soft capsule contains 1.8 mg of soya lecithin. For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Soft capsule (capsule). 

Ofev 100 mg soft capsules
Ofev 100 mg soft capsules are peach-coloured, opaque, oblong soft-gelatin capsules (approx. 16 x 6 mm) marked on one side with the Boehringer Ingelheim company symbol and “100”.

Ofev 150 mg soft capsules
Ofev 150 mg soft capsules are brown-coloured, opaque, oblong soft-gelatin capsules (approx. 18 x 7 mm) marked on one side with the Boehringer Ingelheim company symbol and “150”.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ofev is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF).<br />Ofev is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases<br />(ILDs) with a progressive phenotype (see section 5.1).<br />Ofev is indicated in adults for the treatment of systemic sclerosis associated interstitial lung disease<br />(SSc-ILD).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated by physicians experienced in the management of diseases for which<br />Ofev is approved.<br />Posology<br />The recommended dose is 150 mg nintedanib twice daily administered approximately 12 hours apart.<br />The 100 mg twice daily dose is only recommended to be used in patients who do not tolerate the<br />150 mg twice daily dose.<br />3<br />If a dose is missed, administration should resume at the next scheduled time at the recommended dose.<br />If a dose is missed the patient should not take an additional dose. The recommended maximum daily<br />dose of 300 mg should not be exceeded.<br />Dose adjustments<br />In addition to symptomatic treatment if applicable, the management of adverse reactions to Ofev (see<br />sections 4.4 and 4.8) could include dose reduction and temporary interruption until the specific<br />adverse reaction has resolved to levels that allow continuation of therapy. Ofev treatment may be<br />resumed at the full dose (150 mg twice daily) or a reduced dose (100 mg twice daily). If a patient does<br />not tolerate 100 mg twice daily, treatment with Ofev should be discontinued.<br />If diarrhoea, nausea and/or vomiting persist despite appropriate supportive care (including anti-emetic<br />therapy), dose reduction or treatment interruption may be required. The treatment may be resumed at a<br />reduced dose (100 mg twice daily) or at the full dose (150 mg twice daily). In case of persisting severe<br />diarrhoea, nausea and/or vomiting despite symptomatic treatment, therapy with Ofev should be<br />discontinued (see section 4.4).<br />In case of interruptions due to aspartate aminotransferase (AST) or alanine aminotransferase (ALT)<br />elevations &gt; 3x upper limit of normal (ULN), once transaminases have returned to baseline values,<br />treatment with Ofev may be reintroduced at a reduced dose (100 mg twice daily) which subsequently<br />may be increased to the full dose (150 mg twice daily) (see sections 4.4 and 4.8).<br />Special populations<br />Elderly patients (&ge; 65 years)<br />No overall differences in safety and efficacy were observed for elderly patients. No a-priori dose<br />adjustment is required on the basis of a patient&rsquo;s age. Patients &ge;75 years may be more likely to require<br />dose reduction to manage adverse effects (see section 5.2).<br />Renal impairment<br />Adjustment of the starting dose in patients with mild to moderate renal impairment is not required.<br />The safety, efficacy, and pharmacokinetics of nintedanib have not been studied in patients with severe<br />renal impairment (&lt;30 ml/min creatinine clearance).<br />Hepatic impairment<br />In patients with mild hepatic impairment (Child Pugh A), the recommended dose of Ofev is 100 mg<br />twice daily approximately 12 hours apart. In patients with mild hepatic impairment (Child Pugh A),<br />treatment interruption or discontinuation for management of adverse reactions should be considered.<br />The safety and efficacy of nintedanib have not been investigated in patients with hepatic impairment<br />classified as Child Pugh B and C. Treatment of patients with moderate (Child Pugh B) and severe<br />(Child Pugh C) hepatic impairment with Ofev is not recommended (see section 5.2).</p><p><em>Paediatric population</em></p><p>Nintedanib should not be used in children (see section 4.8 and 5.1).</p><p>Treatment of paediatric patients with nintedanib for fibrosing Interstitial Lung Diseases (ILDs) is not registered.</p><p><br />Method of administration<br />Ofev is for oral use. The capsules should be taken with food, swallowed whole with water, and should<br />not be chewed. The capsule should not be opened or crushed (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pregnancy (see section 4.6)
• Hypersensitivity to nintedanib, to peanut or soya, or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gastrointestinal disorders<br />Diarrhoea<br />In the clinical trials (see section 5.1), diarrhoea was the most frequent gastro-intestinal adverse<br />reaction reported (see section 4.8). In most patients, the adverse reaction was of mild to moderate<br />intensity and occurred within the first 3 months of treatment.<br />Serious cases of diarrhoea leading to dehydration and electrolyte disturbances have been reported in<br />the post-marketing. Patients should be treated at first signs with adequate hydration and anti-diarrhoeal<br />medicinal products, e.g. loperamide, and may require dose reduction or treatment interruption. Ofev<br />treatment may be resumed at a reduced dose (100 mg twice daily) or at the full dose (150 mg twice<br />daily). In case of persisting severe diarrhoea despite symptomatic treatment, therapy with Ofev should<br />be discontinued.<br />Nausea and vomiting<br />Nausea and vomiting were frequently reported gastrointestinal adverse reactions (see section 4.8). In<br />most patients with nausea and vomiting, the event was of mild to moderate intensity. In clinical trials,<br />nausea led to discontinuation of Ofev in up to 2.1% of patients and vomiting led to discontinuation of<br />Ofev in up to 1.4% of patients.<br />If symptoms persist despite appropriate supportive care (including anti-emetic therapy), dose reduction<br />or treatment interruption may be required. The treatment may be resumed at a reduced dose (100 mg<br />twice daily) or at the full dose (150 mg twice daily). In case of persisting severe symptoms therapy<br />with Ofev should be discontinued.<br />Hepatic function<br />The safety and efficacy of Ofev has not been studied in patients with moderate (Child Pugh B) or<br />severe (Child Pugh C) hepatic impairment. Therefore, treatment with Ofev is not recommended in<br />such patients (see section 4.2). Based on increased exposure, the risk for adverse reactions may be<br />increased in patients with mild hepatic impairment (Child Pugh A). Patients with mild hepatic<br />impairment (Child Pugh A) should be treated with a reduced dose of Ofev (see sections 4.2 and 5.2).<br />Cases of drug-induced liver injury have been observed with nintedanib treatment, including severe<br />liver injury with fatal outcome. The majority of hepatic events occur within the first three months of<br />treatment. Therefore, hepatic transaminase and bilirubin levels should be investigated before treatment<br />initiation and during the first month of treatment with Ofev. Patients should then be monitored at<br />regular intervals during the subsequent two months of treatment and periodically thereafter, e.g. at<br />each patient visit or as clinically indicated.<br />Elevations of liver enzymes (ALT, AST, blood alkaline phosphatase (ALKP), gamma-glutamyltransferase<br />(GGT), see section 4.8) and bilirubin were reversible upon dose reduction or interruption in<br />the majority of cases. If transaminase (AST or ALT) elevations &gt; 3x ULN are measured, dose<br />reduction or interruption of the therapy with Ofev is recommended and the patient should be<br />monitored closely. Once transaminases have returned to baseline values, treatment with Ofev may be<br />resumed at the full dose (150 mg twice daily) or reintroduced at a reduced dose (100 mg twice daily)<br />which subsequently may be increased to the full dose (see section 4.2). If any liver test elevations are<br />associated with clinical signs or symptoms of liver injury, e.g. jaundice, treatment with Ofev should be<br />permanently discontinued. Alternative causes of the liver enzyme elevations should be investigated.<br />Patients with low body weight (&lt; 65 kg), Asian and female patients have a higher risk of elevations of<br />liver enzymes. Nintedanib exposure increased linearly with patient age, which may also result in a<br />higher risk of developing liver enzyme elevations (see section 5.2). Close monitoring is recommended<br />in patients with these risk factors.<br />5<br />Renal function<br />Cases of renal impairment/failure, in some cases with fatal outcome, have been reported with<br />nintedanib use (see section 4.8).<br />Patients should be monitored during nintedanib therapy, with particular attention to those patients<br />exhibiting risk factors for renal impairment/failure. In case of renal impairment/failure, therapy<br />adjustment should be considered (see section 4.2 Dose adjustments).<br />Haemorrhage<br />Vascular endothelial growth factor receptor (VEGFR) inhibition might be associated with an increased<br />risk of bleeding.<br />Patients at known risk for bleeding including patients with inherited predisposition to bleeding or<br />patients receiving a full dose of anticoagulative treatment were not included in the clinical trials. Nonserious<br />and serious bleeding events, some of which were fatal, have been reported in the postmarketing<br />period (including patients with or without anticoagulant therapy or other medicinal products<br />that could cause bleeding). Therefore, these patients should only be treated with Ofev if the anticipated<br />benefit outweighs the potential risk.<br />Arterial thromboembolic events<br />Patients with a recent history of myocardial infarction or stroke were excluded from the clinical trials.<br />In the clinical trials, arterial thromboembolic events were infrequently reported (Ofev 2.5% versus<br />placebo 0.7% for INPULSIS; Ofev 0.9% versus placebo 0.9% for INBUILD; Ofev 0.7% versus<br />placebo 0.7% for SENSCIS). In the INPULSIS trials, a higher percentage of patients experienced<br />myocardial infarctions in the Ofev group (1.6%) compared to the placebo group (0.5%), while adverse<br />events reflecting ischaemic heart disease were balanced between the Ofev and placebo groups. In the<br />INBUILD trial, myocardial infarction was observed with low frequency: Ofev 0.9% versus placebo<br />0.9%. In the SENSCIS trial, myocardial infarction was observed with low frequency in the placebo<br />group (0.7%) and not observed in the Ofev group. Caution should be used when treating patients at<br />higher cardiovascular risk including known coronary artery disease. Treatment interruption should be<br />considered in patients who develop signs or symptoms of acute myocardial ischemia.<br />Aneurysms and artery dissections<br />The use of VEGF pathway inhibitors in patients with or without hypertension may promote the<br />formation of aneurysms and/or artery dissections. Before initiating Ofev, this risk should be carefully<br />considered in patients with risk factors such as hypertension or history of aneurysm.<br />Venous thromboembolism<br />In the clinical trials, no increased risk of venous thromboembolism was observed in nintedanib treated<br />patients. Due to the mechanism of action of nintedanib patients might have an increased risk of<br />thromboembolic events.<br />Gastrointestinal perforations and ischaemic colitis<br />In the clinical trials, the frequency of patients with perforation was up to 0.3% in both treatment<br />groups. Due to the mechanism of action of nintedanib, patients might have an increased risk of<br />gastrointestinal perforations. Cases of gastrointestinal perforations and cases of ischaemic colitis,<br />some of which were fatal, have been reported in the post-marketing period. Particular caution should<br />be exercised when treating patients with previous abdominal surgery, previous history of peptic<br />ulceration, diverticular disease or receiving concomitant corticosteroids or NSAIDs. Ofev should only<br />be initiated at least 4 weeks after abdominal surgery. Therapy with Ofev should be permanently<br />discontinued in patients who develop gastrointestinal perforation or ischaemic colitis. Exceptionally,<br />Ofev can be reintroduced after complete resolution of ischaemic colitis and careful assessment of<br />patient&rsquo;s condition and other risk factors.<br />Nephrotic range proteinuria and thrombotic microangiopathy<br />Very few cases of nephrotic range proteinuria with or without renal function impairment have been<br />reported post-marketing. Histological findings in individual cases were consistent with glomerular<br />microangiopathy with or without renal thrombi. Reversal of the symptoms has been observed after<br />6<br />Ofev was discontinued, with residual proteinuria in some cases. Treatment interruption should be<br />considered in patients who develop signs or symptoms of nephrotic syndrome.<br />VEGF pathway inhibitors have been associated with thrombotic microangiopathy (TMA), including<br />very few case reports for nintedanib. If laboratory or clinical findings associated with TMA occur in a<br />patient receiving nintedanib, treatment with nintedanib should be discontinued and thorough<br />evaluation for TMA should be completed.<br />Hypertension<br />Administration of Ofev may increase blood pressure. Systemic blood pressure should be measured<br />periodically and as clinically indicated.<br />Pulmonary hypertension<br />Data on the use of Ofev in patients with pulmonary hypertension is limited.<br />Patients with significant pulmonary hypertension (cardiac index &le; 2 L/min/m&sup2;, or parenteral<br />epoprostenol/treprostinil, or significant right heart failure) were excluded from the INBUILD and<br />SENSCIS trials.<br />Ofev should not be used in patients with severe pulmonary hypertension. Close monitoring is<br />recommended in patients with mild to moderate pulmonary hypertension.<br />Wound healing complication<br />No increased frequency of impaired wound healing was observed in the clinical trials. Based on the<br />mechanism of action nintedanib may impair wound healing. No dedicated studies investigating the<br />effect of nintedanib on wound healing were performed. Treatment with Ofev should therefore only be<br />initiated or - in case of perioperative interruption - resumed based on clinical judgement of adequate<br />wound healing.<br />Co-administration with pirfenidone<br />In a dedicated pharmacokinetic study, concomitant treatment of nintedanib with pirfenidone was<br />investigated in patients with IPF. Based on these results, there is no evidence of a relevant<br />pharmacokinetic drug-drug interaction between nintedanib and pirfenidone when administered in<br />combination (see section 5.2). Given the similarity in safety profiles for both medicinal products,<br />additive adverse reactions, including gastrointestinal and hepatic adverse events, may be expected.<br />The benefit-risk balance of concomitant treatment with pirfenidone has not been established.<br />Effect on QT interval<br />No evidence of QT prolongation was observed for nintedanib in the clinical trial programme<br />(Section 5.1). As some other tyrosine kinase inhibitors are known to exert an effect on QT, caution<br />should be exercised when nintedanib is administered in patients who may develop QTc prolongation.<br />Allergic reaction<br />Dietary soya products are known to cause allergic reactions including severe anaphylaxis in persons<br />with soya allergy. Patients with known allergy to peanut protein carry an enhanced risk for severe<br />reactions to soya preparations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>P-glycoprotein (P-gp)<br />Nintedanib is a substrate of P-gp (see section 5.2). Co-administration with the potent P-gp inhibitor<br />ketoconazole increased exposure to nintedanib 1.61-fold based on AUC and 1.83-fold based on Cmax in<br />a dedicated drug-drug interaction study. In a drug-drug interaction study with the potent P-gp inducer<br />rifampicin, exposure to nintedanib decreased to 50.3% based on AUC and to 60.3% based on Cmax<br />upon co-administration with rifampicin compared to administration of nintedanib alone. If coadministered<br />with Ofev, potent P-gp inhibitors (e.g. ketoconazole, erythromycin or cyclosporine) may<br />increase exposure to nintedanib. In such cases, patients should be monitored closely for tolerability of<br />nintedanib. Management of adverse reactions may require interruption, dose reduction, or<br />discontinuation of therapy with Ofev (see section 4.2).<br />7<br />Potent P-gp inducers (e.g. rifampicin, carbamazepine, phenytoin, and St. John&rsquo;s Wort) may decrease<br />exposure to nintedanib. Selection of an alternate concomitant medicinal product with no or minimal Pgp<br />induction potential should be considered.<br />Cytochrome (CYP)-enzymes<br />Only a minor extent of the biotransformation of nintedanib consisted of CYP pathways. Nintedanib<br />and its metabolites, the free acid moiety BIBF 1202 and its glucuronide BIBF 1202 glucuronide, did<br />not inhibit or induce CYP enzymes in preclinical studies (see section 5.2). The likelihood of drug-drug<br />interactions with nintedanib based on CYP metabolism is therefore considered to be low.<br />Co-administration with other medicinal products<br />Co-administration of nintedanib with oral hormonal contraceptives did not alter the pharmacokinetics<br />of oral hormonal contraceptives to a relevant extent (see section 5.2).<br />Co-administration of nintedanib with bosentan did not alter the pharmacokinetics of nintedanib (see<br />section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential / Contraception<br />Nintedanib may cause foetal harm in humans (see section 5.3). Women of childbearing potential<br />should be advised to avoid becoming pregnant while receiving treatment with Ofev and to use highly<br />effective contraceptive methods at initiation of, during and at least 3 months after the last dose of<br />Ofev. Nintedanib does not relevantly affect the plasma exposure of ethinylestradiol and levonorgestrel<br />(see section 5.2). The efficacy of oral hormonal contraceptives may be compromised by vomiting<br />and/or diarrhoea or other conditions where the absorption may be affected. Women taking oral<br />hormonal contraceptives experiencing these conditions should be advised to use an alternative highly<br />effective contraceptive measure.<br />Pregnancy<br />There is no information on the use of Ofev in pregnant women, but pre-clinical studies in animals have<br />shown reproductive toxicity of this active substance (see section 5.3). As nintedanib may cause foetal<br />harm also in humans, it must not be used during pregnancy (see section 4.3) and pregnancy testing<br />must be conducted prior to treatment with Ofev and during treatment as appropriate.<br />Female patients should be advised to notify their doctor or pharmacist if they become pregnant during<br />therapy with Ofev.<br />If the patient becomes pregnant while receiving Ofev, treatment must be discontinued and she should<br />be apprised of the potential hazard to the foetus.<br />Breast-feeding<br />There is no information on the excretion of nintedanib and its metabolites in human milk.<br />Pre-clinical studies showed that small amounts of nintedanib and its metabolites (&le; 0.5% of the<br />administered dose) were secreted into milk of lactating rats. A risk to the newborns/infants cannot be<br />excluded. Breast-feeding should be discontinued during treatment with Ofev.<br />Fertility<br />Based on preclinical investigations there is no evidence for impairment of male fertility (see<br />section 5.3). From subchronic and chronic toxicity studies, there is no evidence that female fertility in<br />rats is impaired at a systemic exposure level comparable with that at the maximum recommended<br />human dose (MRHD) of 150 mg twice daily (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ofev has minor influence on the ability to drive and use machines. Patients should be advised to be<br />cautious when driving or using machines during treatment with Ofev.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />In clinical trials and during the post-marketing experience, the most frequently reported adverse<br />reactions associated with the use of nintedanib included diarrhoea, nausea and vomiting, abdominal<br />pain, decreased appetite, weight decreased and hepatic enzyme increased.<br />For the management of selected adverse reactions see section 4.4.<br />Tabulated list of adverse reactions<br />Table 1 provides a summary of the adverse drug reactions (ADRs) by MedDRA System Organ Class<br />(SOC) and frequency category using the following convention: very common (&ge; 1/10), common<br />(&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare<br />(&lt; 1/10,000), not known (cannot be estimated from the available data).<br />Table 1: Summary of ADRs per frequency category<br />Frequency<br />System Organ Class<br />preferred term<br />Idiopathic<br />pulmonary<br />fibrosis<br />Other chronic<br />fibrosing ILDs with a<br />progressive<br />phenotype<br />Systemic sclerosis<br />associated interstitial<br />lung disease<br />Blood and lymphatic system disorders<br />Thrombocytopenia Uncommon Uncommon Uncommon<br />Metabolism and nutrition disorders<br />Weight decreased Common Common Common<br />Decreased appetite Common Very common Common<br />Dehydration Uncommon Uncommon Not known<br />Cardiac disorders<br />Myocardial<br />infarction<br />Uncommon Uncommon Not known<br />Vascular disorders<br />Bleeding (see<br />section 4.4)<br />Common Common Common<br />Hypertension Uncommon Common Common<br />Aneurysms and<br />artery dissections<br />Not known Not known Not known<br />Gastrointestinal disorder<br />Diarrhoea Very common Very common Very common<br />Nausea Very common Very common Very common<br />Abdominal pain Very common Very common Very common<br />Vomiting Common Very common Very common<br />Pancreatitis Uncommon Uncommon Not known<br />Colitis Uncommon Uncommon Uncommon<br />Hepatobiliary disorders<br />Drug induced liver<br />injury<br />Uncommon Common Uncommon<br />Hepatic enzyme<br />increased<br />Very common Very common Very common<br />Alanine<br />aminotransferase<br />Common Very common Common<br />9<br />Frequency<br />System Organ Class<br />preferred term<br />Idiopathic<br />pulmonary<br />fibrosis<br />Other chronic<br />fibrosing ILDs with a<br />progressive<br />phenotype<br />Systemic sclerosis<br />associated interstitial<br />lung disease<br />(ALT) increased<br />Aspartate<br />aminotransferase<br />(AST) increased<br />Common Common Common<br />Gamma glutamyl<br />transferase (GGT)<br />increased<br />Common Common Common<br />Hyperbilirubinaemia Uncommon Uncommon Not known<br />Blood alkaline<br />phosphatase (ALKP)<br />increased<br />Uncommon Common Common<br />Skin and subcutaneous tissue disorders<br />Rash Common Common Uncommon<br />Pruritus Uncommon Uncommon Uncommon<br />Alopecia Uncommon Uncommon Not known<br />Renal and urinary disorders<br />Renal failure (see<br />section 4.4)<br />Not known Not known Uncommon<br />Proteinuria Uncommon Uncommon Not known<br />Nervous system disorders<br />Headache Common Common Common<br />Description of selected adverse reactions<br />Diarrhoea<br />In clinical trials (see section 5.1), diarrhoea was the most frequent gastro-intestinal event reported. In<br />most patients, the event was of mild to moderate intensity. More than two thirds of patients<br />experiencing diarrhoea reported its first onset already during the first three months of treatment. In<br />most patients, the events were managed by anti-diarrhoeal therapy, dose reduction or treatment<br />interruption (see section 4.4). An overview of the reported diarrhoea events in the clinical trials is<br />listed in Table 2:<br />Table 2: Diarrhoea in clinical trials over 52 weeks<br />INPULSIS INBUILD SENSCIS<br />Placebo Ofev Placebo Ofev Placebo Ofev<br />Diarrhoea 18.4% 62.4% 23.9% 66.9% 31.6% 75.7%<br />Severe diarrhoea 0.5% 3.3% 0.9% 2.4% 1.0% 4.2%<br />Diarrhoea<br />leading to Ofev<br />dose reduction<br />0%<br />10.7%<br />0.9%<br />16.0%<br />1.0%<br />22.2%<br />Diarrhoea<br />leading to Ofev<br />discontinuation<br />0.2%<br />4.4%<br />0.3%<br />5.7%<br />0.3%<br />6.9%<br />Hepatic enzyme increased<br />In the INPULSIS trials, liver enzyme elevations (see section 4.4) were reported in 13.6% versus 2.6%<br />of patients treated with Ofev and placebo, respectively. In the INBUILD trial, liver enzyme elevations<br />were reported in 22.6% versus 5.7% of patients treated with Ofev and placebo, respectively. In the<br />SENSCIS trial, liver enzyme elevations were reported in 13.2% versus 3.1% of patients treated with<br />10<br />&bull; The National Pharmacovigilance Centre (NPC):<br />- Fax: +966 11 205 7662<br />- Call NPC at +966-11-2038222, Ext 2317-2356-2340<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/<br />Ofev and placebo, respectively. Elevations of liver enzymes were reversible and not associated with<br />clinically manifest liver disease.<br />For further information about special populations, recommended measures and dosing adjustments in<br />case of diarrhoea and hepatic enzyme increased, refer additionally to sections 4.4 and 4.2,<br />respectively.<br />Bleeding<br />In clinical trials, the frequency of patients who experienced bleeding was slightly higher in patients<br />treated with Ofev or comparable between the treatment arms (Ofev 10.3% versus placebo 7.8% for<br />INPULSIS; Ofev 11.1% versus placebo 12.7% for INBUILD; Ofev 11.1% versus placebo 8.3% for<br />SENSCIS). Non-serious epistaxis was the most frequent bleeding event reported. Serious bleeding<br />events occurred with low frequencies in the 2 treatment groups (Ofev 1.3% versus placebo 1.4% for<br />INPULSIS; Ofev 0.9% versus placebo 1.5% for INBUILD; Ofev 1.4% versus placebo 0.7% for<br />SENSCIS).<br />Post-marketing bleeding events include but are not limited to gastrointestinal, respiratory and central<br />nervous organ systems, with the most frequent being gastrointestinal (see section 4.4).<br />Proteinuria<br />In clinical trials, the frequency of patients who experienced proteinuria was low and comparable<br />between the treatment arms (Ofev 0.8% versus placebo 0.5% for INPULSIS; Ofev 1.5% versus<br />placebo 1.8% for INBUILD; Ofev 1.0% versus placebo 0.0% for SENSCIS). Nephrotic syndrome has<br />not been reported in clinical trials. Very few cases of nephrotic range proteinuria with or without renal<br />function impairment have been reported post-marketing. Histological findings in individual cases were<br />consistent with glomerular microangiopathy with or without renal thrombi. Reversal of the symptoms<br />has been observed after Ofev was discontinued, with residual proteinuria in some cases. Treatment<br />interruption should be considered in patients who develop signs or symptoms of nephrotic syndrome<br />(see section 4.4).<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It<br />allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare<br />professionals are asked to report any suspected adverse reactions via the national reporting system<br />&bull; Saudi Arabia<br />&bull; Other GCC States:<br />- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific antidote or treatment for Ofev overdose. Two patients in the oncology programme<br />had an overdose of maximum 600 mg twice daily up to eight days. Observed adverse reactions were<br />consistent with the known safety profile of nintedanib, i.e. increased liver enzymes and gastrointestinal<br />symptoms. Both patients recovered from these adverse reactions. In the INPULSIS trials, one patient<br />was inadvertently exposed to a dose of 600 mg daily for a total of 21 days. A non-serious adverse<br />11<br />event (nasopharyngitis) occurred and resolved during the period of incorrect dosing, with no onset of<br />other reported events. In case of overdose, treatment should be interrupted and general supportive<br />measures initiated as appropriate.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EX09 <u>Mechanism of action</u></p><p>Nintedanib is a small molecule tyrosine kinase inhibitor including the receptors platelet-derived</p><p>growth factor receptor (PDGFR) &alpha; and &beta;, fibroblast growth factor receptor (FGFR) 1-3, and VEGFR 1-3. In addition, nintedanib inhibits Lck (lymphocyte-specific tyrosine-protein kinase), Lyn (tyrosine-protein kinase lyn), Src (proto-oncogene tyrosine-protein kinase src), and CSF1R (colony stimulating factor 1 receptor) kinases. Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these kinases and blocks the intracellular signalling cascades, which have been demonstrated to be involved in the pathogenesis of fibrotic tissue remodelling in interstitial lung diseases.</p><p><u>Pharmacodynamic effects</u></p><p>In <em>in vitro </em>studies using human cells nintedanib has been shown to inhibit processes assumed to be involved in the initiation of the fibrotic pathogenesis, the release of pro-fibrotic mediators from peripheral blood monocytic cells and macrophage polarisation to alternatively activated macrophages. Nintedanib has been demonstrated to inhibit fundamental processes in organ fibrosis, proliferation and migration of fibroblasts and transformation to the active myofibroblast phenotype and secretion of extracellular matrix. In animal studies in multiple models of IPF, SSc/SSc-ILD, rheumatoid arthritis- associated-(RA-)ILD and other organ fibrosis, nintedanib has shown anti-inflammatory effects and anti-fibrotic effects in the lung, skin, heart, kidney, and liver. Nintedanib also exerted vascular activity. It reduced dermal microvascular endothelial cell apoptosis and attenuated pulmonary vascular remodelling by reducing the proliferation of vascular smooth muscle cells, the thickness of pulmonary vessel walls and percentage of occluded pulmonary vessels.</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>Idiopathic pulmonary fibrosis (IPF)</em></p><p><em>&nbsp;</em></p><p>The clinical efficacy of nintedanib has been studied in patients with IPF in two phase III, randomised, double-blind, placebo-controlled studies with identical design (INPULSIS-1 (1199.32) and INPULSIS-2 (1199.34)). Patients with FVC baseline &lt; 50% predicted or carbon monoxide diffusing capacity (DLCO, corrected for haemoglobin) &lt; 30% predicted at baseline were excluded from the trials. Patients were randomized in a 3:2 ratio to treatment with Ofev 150 mg or placebo twice daily for 52 weeks.</p><p>The primary endpoint was the annual rate of decline in forced vital capacity (FVC). The key secondary endpoints were change from baseline in Saint George&#39;s Respiratory Questionnaire (SGRQ) total score at 52 weeks and time to first acute IPF exacerbation.</p><p><em><u>Annual rate of decline in FVC</u></em></p><p>The annual rate of decline of FVC (in mL) was significantly reduced in patients receiving nintedanib compared to patients receiving placebo. The treatment effect was consistent in both trials. See Table 3 for individual and pooled study results.</p><p>&nbsp;</p><p>Table 3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Annual rate of decline in FVC (mL) in trials INPULSIS-1, INPULSIS-2 and their pooled data - treated set</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>INPULSIS-1</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>INPULSIS-2</p></td><td colspan="2" style="vertical-align:top"><p>INPULSIS-1 and INPULSIS-2</p><p>pooled</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Number of</p><p>analysed patients</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>204</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>309</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>219</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>329</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>423</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>638</p></td></tr><tr><td style="vertical-align:top"><p>Rate<sup>1</sup> (SE) of decline over 52</p><p>weeks</p></td><td style="vertical-align:top"><p>&minus;239.9</p><p>(18.71)</p></td><td style="vertical-align:top"><p>&minus;114.7</p><p>(15.33)</p></td><td style="vertical-align:top"><p>&minus;207.3</p><p>(19.31)</p></td><td style="vertical-align:top"><p>&minus;113.6</p><p>(15.73)</p></td><td style="vertical-align:top"><p>&minus;223.5</p><p>(13.45)</p></td><td style="vertical-align:top"><p>&minus;113.6</p><p>(10.98)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Comparison vs placebo</p></td></tr><tr><td style="vertical-align:top"><p>Difference<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>125.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>93.7</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>109.9</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(77.7,</p><p>172.8)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(44.8,</p><p>142.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(75.9,</p><p>144.0)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0002</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr></tbody></table><p><sup>1</sup> Estimated based on a random coefficient regression model. CI: confidence interval</p><p>&nbsp;</p><p>In a sensitivity analysis which assumed that in patients with missing data at week 52 the FVC decline after the last observed value would be the same as in all placebo patients, the adjusted difference in the annual rate of decline between nintedanib and placebo was 113.9 mL/year (95% CI 69.2, 158.5) in INPULSIS-1 and 83.3 mL/year (95% CI 37.6, 129.0) in INPULSIS-2<strong>.</strong></p><p>See Figure 1 for the evolution of change from baseline over time in both treatment groups, based on the pooled analysis of studies INPULSIS-1 and INPULSIS-2.</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype id="_x0000_t75"
  coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
  filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Image_x0020_3" o:spid="_x0000_s1028" type="#_x0000_t75"
  style='position:absolute;left:0;text-align:left;margin-left:72.5pt;
  margin-top:27.8pt;width:432.8pt;height:258.6pt;z-index:-251658239;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
   o:title=""/>
  <o:lock v:ext="edit" aspectratio="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="577" height="345" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />Figure 1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean (SEM) observed FVC change from baseline (mL) over time, studies INPULSIS-1 and INPULSIS-2 pooled</p><p>bid = twice daily</p><p>&nbsp;</p><p><em><u>FVC responder analysis</u></em></p><p>In both INPULSIS trials, the proportion of FVC responders, defined as patients with an absolute decline in FVC % predicted no greater than 5% (a threshold indicative of the increasing risk of mortality in IPF), was significantly higher in the nintedanib group as compared to placebo. Similar results were observed in analyses using a conservative threshold of 10%. See Table 4 for individual and pooled study results.</p><p>Table 4:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proportion of FVC responders at 52 weeks in trials INPULSIS-1, INPULSIS-2 and their pooled data - treated set</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>INPULSIS-1</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>INPULSIS-2</p></td><td colspan="2" style="vertical-align:top"><p>INPULSIS-1 and INPULSIS-2</p><p>pooled</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Number of</p><p>analysed patients</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>204</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>309</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>219</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>329</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>423</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>638</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>5% threshold</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of FVC</p><p>responders<sup>1</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>78 (38.2)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>163 (52.8)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>86 (39.3)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>175 (53.2)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>164 (38.8)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>338 (53.0)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Comparison vs placebo</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.85</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.79</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.84</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(1.28, 2.66)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(1.26, 2.55)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(1.43, 2.36)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>2</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0010</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0011</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>10% threshold</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of FVC</p><p>responders<sup>1</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>116 (56.9)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>218 (70.6)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>140 (63.9)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>229 (69.6)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>256 (60.5)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>447 (70.1)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Comparison vs placebo</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.91</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.29</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.58</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(1.32, 2.79)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.89, 1.86)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(1.21, 2.05)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>2</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0007</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.1833</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0007</p></td></tr></tbody></table><p><sup>1</sup>Responder patients are those with no absolute decline greater than 5% or greater than 10% in FVC % predicted, depending on the threshold and with an FVC evaluation at 52 weeks.</p><p><sup>2</sup>Based on a logistic regression.</p><p>&nbsp;</p><p><em><u>Time to progression (&ge; 10% absolute decline of FVC % predicted or death)</u></em></p><p>In both INPULSIS trials, the risk of progression was statistically significantly reduced for patients treated with nintedanib compared with placebo. In the pooled analysis, the HR was 0.60 indicating a 40% reduction in the risk of progression for patients treated with nintedanib compared with placebo.</p><p>&nbsp;</p><p>Table 5:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency of patients with <u>&ge;</u> 10% absolute decline of FVC % predicted or death over 52 weeks and time to progression in trials INPULSIS-1, INPULSIS-2, and their pooled data - treated set</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>INPULSIS-1</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>INPULSIS-2</p></td><td colspan="2" style="vertical-align:top"><p>INPULSIS-1 and INPULSIS-2</p><p>pooled</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Number at risk</p></td><td style="vertical-align:top"><p>204</p></td><td style="vertical-align:top"><p>309</p></td><td style="vertical-align:top"><p>219</p></td><td style="vertical-align:top"><p>329</p></td><td style="vertical-align:top"><p>423</p></td><td style="vertical-align:top"><p>638</p></td></tr><tr><td style="vertical-align:top"><p>Patients with events, N (%)</p></td><td style="vertical-align:top"><p>83</p><p>(40.7)</p></td><td style="vertical-align:top"><p>75</p><p>(24.3)</p></td><td style="vertical-align:top"><p>92</p><p>(42.0)</p></td><td style="vertical-align:top"><p>98</p><p>(29.8)</p></td><td style="vertical-align:top"><p>175</p><p>(41.4)</p></td><td style="vertical-align:top"><p>173</p><p>(27.1)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Comparison vs placebo<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>2</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0054</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>3</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.53</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.67</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.60</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.39, 0.72)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.51, 0.89)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.49, 0.74)</p></td></tr></tbody></table><p><sup>1</sup> Based on data collected up to 372 days (52 weeks + 7 day margin).</p><p><sup>2</sup> Based on a Log-rank test.</p><p><sup>3</sup> Based on a Cox&rsquo;s regression model.</p><p>&nbsp;</p><p><em><u>Change from baseline in SGRQ total score at week 52</u></em></p><p>In the pooled analysis of the INPULSIS trials, the baseline SGRQ scores were 39.51 in the nintedanib group and 39.58 in the placebo group. The estimated mean change from baseline to week 52 in SGRQ total score was smaller in the nintedanib group (3.53) than in the placebo group (4.96), with a difference between the treatment groups of -1.43 (95% CI: -3.09, 0.23; p=0.0923). Overall, the effect of nintedanib on health-related quality of life as measured by the SGRQ total score is modest, indicating less worsening compared to placebo.</p><p><em><u>Time to first acute IPF exacerbation</u></em></p><p>In the pooled analysis of the INPULSIS trials, a numerically lower risk of first acute exacerbation was observed in patients receiving nintedanib compared to placebo. See Table 6 for individual and pooled study results.</p><p>&nbsp;</p><p>Table 6:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency of patients with acute IPF exacerbations over 52 weeks and time to first exacerbation analysis based on investigator-reported events in trials INPULSIS-1, INPULSIS-2, and their pooled data - treated set</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>INPULSIS-1</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>INPULSIS-2</p></td><td colspan="2" style="vertical-align:top"><p>INPULSIS-1 and INPULSIS-2</p><p>pooled</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Number at risk</p></td><td style="vertical-align:top"><p>204</p></td><td style="vertical-align:top"><p>309</p></td><td style="vertical-align:top"><p>219</p></td><td style="vertical-align:top"><p>329</p></td><td style="vertical-align:top"><p>423</p></td><td style="vertical-align:top"><p>638</p></td></tr><tr><td style="vertical-align:top"><p>Patients with events, N (%)</p></td><td style="vertical-align:top"><p>11 (5.4)</p></td><td style="vertical-align:top"><p>19 (6.1)</p></td><td style="vertical-align:top"><p>21 (9.6)</p></td><td style="vertical-align:top"><p>12 (3.6)</p></td><td style="vertical-align:top"><p>32 (7.6)</p></td><td style="vertical-align:top"><p>31 (4.9)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Comparison vs placebo<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>2</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.6728</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0050</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0823</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>3</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.15</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.38</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.64</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.54, 2.42)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.19, 0.77)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.39, 1.05)</p></td></tr></tbody></table><p><sup>1</sup> Based on data collected up to 372 days (52 weeks + 7 day margin).</p><p><sup>2</sup> Based on a Log-rank test.</p><p><sup>3</sup> Based on a Cox&rsquo;s regression model.</p><p>&nbsp;</p><p>In a pre-specified sensitivity analysis, the frequency of patients with at least 1 adjudicated exacerbation occurring within 52 weeks was lower in the nintedanib group (1.9% of patients) than in</p><p>&nbsp;</p><p>the placebo group (5.7% of patients). Time to event analysis of the adjudicated exacerbation events using pooled data yielded a hazard ratio (HR) of 0.32 (95% CI 0.16, 0.65; p=0.0010).</p><p><em><u>Survival analysis</u></em></p><p>In the pre-specified pooled analysis of survival data of the INPULSIS trials, overall mortality over 52 weeks was lower in the nintedanib group (5.5%) compared with the placebo group (7.8%). The analysis of time to death resulted in a HR of 0.70 (95% CI 0.43, 1.12; p=0.1399). The results of all survival endpoints (such as on-treatment mortality and respiratory mortality) showed a consistent numerical difference in favour of nintedanib.</p><p>&nbsp;</p><p>Table 7:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All-cause mortality over 52 weeks in trials INPULSIS-1, INPULSIS-2, and their pooled data - treated set</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>INPULSIS-1</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>INPULSIS-2</p></td><td colspan="2" style="vertical-align:top"><p>INPULSIS-1 and INPULSIS-2</p><p>pooled</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev 150 mg</p><p>twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Number at risk</p></td><td style="vertical-align:top"><p>204</p></td><td style="vertical-align:top"><p>309</p></td><td style="vertical-align:top"><p>219</p></td><td style="vertical-align:top"><p>329</p></td><td style="vertical-align:top"><p>423</p></td><td style="vertical-align:top"><p>638</p></td></tr><tr><td style="vertical-align:top"><p>Patients with events, N (%)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>13 (6.4)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>13 (4.2)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>20 (9.1)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>22 (6.7)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>33 (7.8)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>35 (5.5)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Comparison vs placebo<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>2</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.2880</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.2995</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.1399</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>3</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.63</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.74</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.70</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.29, 1.36)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.40, 1.35)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.43, 1.12)</p></td></tr></tbody></table><p><sup>1</sup> Based on data collected up to 372 days (52 weeks + 7 day margin).</p><p><sup>2</sup> Based on a Log-rank test.</p><p><sup>3</sup> Based on a Cox&rsquo;s regression model.</p><p>&nbsp;</p><p><em><u>Long-term treatment with Ofev in patients with IPF (INPULSIS-ON)</u></em></p><p>An open-label extension trial of Ofev included 734 patients with IPF. Patients who completed the 52- week treatment period in an INPULSIS trial received open-label Ofev treatment in the extension trial INPULSIS-ON. Median exposure time for patients treated with Ofev in both the INPULSIS and INPULSIS-ON trials was 44.7 months (range 11.9 &ndash; 68.3). The exploratory efficacy endpoints included the annual rate of decline in FVC over 192 weeks which was &minus;135.1 (5.8) mL/year in all patients treated and were consistent with the annual rate of FVC decline in patients treated with Ofev in the INPULSIS phase III trials (&minus;113.6 mL per year). The adverse event profile of Ofev in INPULSIS-ON was consistent to that in the INPULSIS phase III trials.</p><p><em><u>IPF patients with advanced lung function impairment (INSTAGE)</u></em></p><p>INSTAGE was a multicentre, multinational, prospective, randomised, double-blind, parallel-group clinical trial in IPF patients with advanced lung function impairment (DLCO &le; 35% predicted) for 24 weeks. 136 patients were treated with Ofev monotherapy. Primary endpoint result showed a reduction of St Georges Respiratory Questionnaire (SGRQ) total score by -0.77 units at week W12, based on adjusted mean change from baseline. A post hoc comparison demonstrated that the decline in FVC in these patients was consistent with the decline in FVC in patients with less advanced disease and treated with Ofev in the INPULSIS phase III trials.</p><p>The safety and tolerability profile of Ofev in IPF patients with advanced lung function impairment was consistent with that seen in the INPULSIS phase III trials.</p><p><em><u>Additional data from the phase IV INJOURNEY trial with Ofev 150 mg twice daily and add-on</u> <u>pirfenidone</u></em></p><p>Concomitant treatment with nintedanib and pirfenidone has been investigated in an exploratory open- label, randomised trial of nintedanib 150 mg twice daily with add-on pirfenidone (titrated to 801 mg three times a day) compared to nintedanib 150 mg twice daily alone in 105 randomised patients for 12</p><p>&nbsp;</p><p>weeks. The primary endpoint was the percentage of patients with gastrointestinal adverse events from baseline to week 12. Gastrointestinal adverse events were frequent and in line with the established safety profile of each component. Diarrhoea, nausea and vomiting were the most frequent adverse events reported in patients, treated with pirfenidone added to nintedanib versus nintedanib alone, respectively.</p><p>Mean (SE) absolute changes from baseline in FVC at week 12 were &minus;13.3 (17.4) mL in patients treated with nintedanib with add-on pirfenidone (n=48) compared to &minus;40.9 (31.4) mL in patients treated with nintedanib alone (n=44).</p><p><em>Other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype</em></p><p><em>&nbsp;</em></p><p>The clinical efficacy of Ofev has been studied in patients with other chronic fibrosing ILDs with a progressive phenotype in a double-blind, randomised, placebo-controlled phase III trial (INBUILD). Patients with IPF were excluded. Patients with a clinical diagnosis of a chronic fibrosing ILD were selected if they had relevant fibrosis (greater than 10% fibrotic features) on HRCT and presented with clinical signs of progression (defined as FVC decline &ge;10%, FVC decline &ge; 5% and &lt;10% with worsening symptoms or imaging, or worsening symptoms and worsening imaging all in the 24 months prior to screening). Patients were required to have an FVC greater than or equal to 45% of predicted and a DLCO 30% to less than 80% of predicted. Patients were required to have progressed despite management deemed appropriate in clinical practice for the patient&rsquo;s relevant ILD.</p><p>A total of 663 patients were randomised in a 1:1 ratio to receive either Ofev 150 mg bid or matching placebo for at least 52 weeks. The median Ofev exposure over the whole trial was 17.4 months and the mean Ofev exposure over the whole trial was 15.6 months. Randomisation was stratified based on HRCT fibrotic pattern as assessed by central readers. 412 patients with HRCT with usual interstitial pneumonia (UIP)-like fibrotic pattern and 251 patients with other HRCT fibrotic patterns were randomised. There were 2 co-primary populations defined for the analyses in this trial: all patients (the overall population) and patients with HRCT with UIP-like fibrotic pattern. Patients with other HRCT fibrotic patterns represented the &lsquo;complementary&rsquo; population.</p><p>The primary endpoint was the annual rate of decline in forced vital capacity (FVC) (in mL) over</p><p>52 weeks. Main secondary endpoints were absolute change from baseline in King&#39;s Brief Interstitial Lung Disease Questionnaire (K-BILD) total score at week 52, time to first acute ILD exacerbation or death over 52 weeks, and time to death over 52 weeks.</p><p>Patients had a mean (standard deviation [SD, Min-Max]) age of 65.8 (9.8, 27-87) years and a mean FVC percent predicted of 69.0% (15.6, 42-137). The underlying clinical ILD diagnoses in groups represented in the trial were hypersensitivity pneumonitis (26.1%), autoimmune ILDs (25.6%), idiopathic nonspecific interstitial pneumonia (18.9%), unclassifiable idiopathic interstitial pneumonia (17.2%), and other ILDs (12.2%).</p><p>&nbsp;</p><p>The INBUILD trial was not designed or powered to provide evidence for a benefit of nintedanib in specific diagnostic subgroups. Consistent effects were demonstrated in subgroups based on the ILD diagnoses. The experience with nintedanib in very rare progressive fibrosing ILDs is limited.</p><p><em><u>Annual rate of decline in FVC</u></em></p><p>The annual rate of decline in FVC (in mL) over 52 weeks was significantly reduced by 107.0 mL in patients receiving Ofev compared to patients receiving placebo (Table 8) corresponding to a relative treatment effect of 57.0%.</p><p>&nbsp;</p><p>Table 8:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Annual rate of decline in FVC (mL) over 52 weeks</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev</p><p>150 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Number of analysed patients</p></td><td style="vertical-align:top"><p>331</p></td><td style="vertical-align:top"><p>332</p></td></tr><tr><td style="vertical-align:top"><p>Rate<sup>1</sup> (SE) of decline over</p><p>52 weeks</p></td><td style="vertical-align:top"><p>-187.8 (14.8)</p></td><td style="vertical-align:top"><p>-80.8 (15.1)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Comparison vs placebo</p></td></tr><tr><td style="vertical-align:top"><p>Difference<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>107.0</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(65.4, 148.5)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 0.0001</p></td></tr></tbody></table><p><sup>1</sup>Based on a random coefficient regression with fixed categorical effects of treatment, HRCT pattern, fixed continuous effects of time, baseline FVC [mL], and including treatment-by-time and baseline-by-time interactions</p><p>&nbsp;</p><p>Similar results were observed in the co-primary population of patients with HRCT with UIP-like fibrotic pattern. The treatment effect was consistent in the complementary population of patients with other HRCT fibrotic patterns (interaction p-value 0.2268) (Figure 2).</p><p>&nbsp;</p><p>Figure 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Forest plot of the annual rate of decline in FVC (mL) over 52 weeks in the patient populations</p><p><!--[if gte vml 1]><v:shape
 id="Image_x0020_4" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:428pt;
 height:317pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
  o:title=""/>
 <o:lock v:ext="edit" aspectratio="f"/>
</v:shape><![endif]--><img width="571" height="423" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></p><p>bid = twice daily</p><p>&nbsp;</p><p>The results of the effect of Ofev in reducing the annual rate of decline in FVC were confirmed by all pre-specified sensitivity analyses and consistent results were observed in the pre-specified efficacy subgroups: gender, age group, race, predicted baseline FVC %, and original underlying clinical ILD diagnosis in groups.</p><p>Figure 3 shows the evolution of change in FVC from baseline over time in the treatment groups.</p><p>&nbsp;</p><p>Figure 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean (SEM) observed FVC change from baseline (mL) over 52 weeks</p><p><!--[if gte vml 1]><v:shape
 id="Image_x0020_5" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:428pt;
 height:330pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
  o:title=""/>
 <o:lock v:ext="edit" aspectratio="f"/>
</v:shape><![endif]--><img width="571" height="440" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></p><p>bid = twice daily</p><p>&nbsp;</p><p>In addition, favourable effects of Ofev were observed on the adjusted mean absolute change from baseline in FVC % predicted at week 52. The adjusted mean absolute change from baseline to week 52 in FVC % predicted was lower in the nintedanib group (-2.62%) than in the placebo group (-5.86%).</p><p>The adjusted mean difference between the treatment groups was 3.24 (95% CI: 2.09, 4.40, nominal p&lt;0.0001).</p><p><em><u>FVC responder analysis</u></em></p><p>The proportion of FVC responders, defined as patients with a relative decline in FVC % predicted no greater than 5%, was higher in the Ofev group as compared to placebo. Similar results were observed in analyses using a threshold of 10% (Table 9).</p><p>&nbsp;</p><p>Table 9:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proportion of FVC responders at 52 weeks in INBUILD</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev</p><p>150 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Number of analysed patients</p></td><td style="vertical-align:top"><p>331</p></td><td style="vertical-align:top"><p>332</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>5% threshold</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of FVC responders<sup>1</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>104 (31.4)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>158 (47.6)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Comparison vs placebo</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio&sup2;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2.01</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(1.46, 2.76)</p></td></tr><tr><td style="vertical-align:top"><p>Nominal p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>10% threshold</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of FVC responders<sup>1</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>169 (51.1)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>197 (59.3)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Comparison vs placebo</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio&sup2;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.42</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(1.04, 1.94)</p></td></tr><tr><td style="vertical-align:top"><p>Nominal p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.0268</p></td></tr></tbody></table><p><sup>1</sup>Responder patients are those with no relative decline greater than 5% or greater than 10% in FVC % predicted, depending on the threshold and with an FVC evaluation at 52 weeks (patients with missing data at week 52 were considered as non-responders).</p><p><sup>2</sup>Based on a logistic regression model with continuous covariate baseline FVC % predicted and binary covariate HRCT pattern</p><p>&nbsp;</p><p><em><u>Time to first acute ILD exacerbation or death</u></em></p><p>Over the whole trial, the proportion of patients with at least one event of first acute ILD exacerbation or death was 13.9% in the Ofev group and 19.6% in the placebo group. The HR was 0.67 (95% CI: 0.46, 0.98; nominal p=0.0387), indicating a 33% reduction in the risk of first acute ILD exacerbation or death in patients receiving Ofev compared to placebo (Figure 4).</p><p>&nbsp;</p><p>Figure 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan&ndash;Meier plot of time to first acute ILD exacerbation or death over the whole trial</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Image_x0020_6" o:spid="_x0000_s1027" type="#_x0000_t75" style='position:absolute;
  margin-left:80.15pt;margin-top:7.7pt;width:435.85pt;height:326.9pt;z-index:-251658238;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
   o:title=""/>
  <o:lock v:ext="edit" aspectratio="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="581" height="436" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image008.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>bid = twice daily</p><p>&nbsp;</p><p><em><u>Survival analysis</u></em></p><p>The risk of death was lower in the Ofev group compared to the placebo group. The HR was 0.78 (95% CI: 0.50, 1.21; nominal p=0.2594), indicating a 22% reduction in the risk of death in patients receiving Ofev compared to placebo.</p><p>&nbsp;</p><p><em><u>Time to progression (&ge; 10% absolute decline of FVC % predicted) or death</u></em></p><p>In the INBUILD trial, the risk of progression (&ge; 10% absolute decline of FVC % predicted) or death was reduced for patients treated with Ofev. The proportion of patients with an event was 40.4% in the Ofev group and 54.7% in the placebo group. The HR was 0.66 (95% CI: 0.53, 0.83; p=0.0003), indicating a 34% reduction of the risk of progression (&ge; 10% absolute decline of FVC % predicted) or death in patients receiving Ofev compared to placebo.</p><p><em><u>Quality of life</u></em></p><p>The adjusted mean change from baseline in K-BILD total score at week 52 was -0.79 units in the placebo group and 0.55 in the Ofev group. The difference between the treatment groups was 1.34 (95% CI: -0.31, 2.98; nominal p=0.1115).</p><p>&nbsp;</p><p>The adjusted mean absolute change from baseline in Living with Pulmonary Fibrosis (L-PF) symptoms dyspnoea domain score at week 52 was 4.28 in the Ofev group compared with 7.81 in the placebo group. The adjusted mean difference between the groups in favour of Ofev was -3.53 (95% CI: -6.14, -0.92; nominal p=0.0081). The adjusted mean absolute change from baseline in L-PF Symptoms cough domain score at week 52 was -1.84 in the Ofev group compared with 4.25 in the placebo group. The adjusted mean difference between the groups in favour of Ofev was -6.09 (95% CI: -9.65, -2.53; nominal p=0.0008).</p><p>&nbsp;</p><p><em>Systemic sclerosis associated interstitial lung disease (SSc-ILD)</em></p><p><em>&nbsp;</em></p><p>The clinical efficacy of Ofev has been studied in in patients with SSc-ILD in a double-blind, randomised, placebo-controlled phase III trial (SENSCIS). Patients were diagnosed with SSc-ILD based upon the 2013 American College of Rheumatology / European League Against Rheumatism classification criteria for SSc and a chest high resolution computed tomography (HRCT) scan conducted within the previous 12 months. A total of 580 patients were randomised in a 1:1 ratio to receive either Ofev 150 mg bid or matching placebo for at least 52 weeks, of which 576 patients were treated. Randomisation was stratified by antitopoisomerase antibody status (ATA). Individual patients stayed on blinded trial treatment for up to 100 weeks (median Ofev exposure 15.4 months; mean Ofev exposure 14.5 months).</p><p>&nbsp;</p><p>The primary endpoint was the annual rate of decline in FVC over 52 weeks. Key secondary endpoints were absolute change from baseline in the modified Rodnan Skin Score (mRSS) at week 52 and absolute change from baseline in the Saint George&rsquo;s Respiratory Questionnaire (SGRQ) total score at week 52.</p><p>&nbsp;</p><p>In the overall population, 75.2% of the patients were female. The mean (standard deviation [SD, Min- Max]) age was 54.0 (12.2, 20-79) years. Overall, 51.9% of patients had diffuse cutaneous systemic sclerosis (SSc) and 48.1% had limited cutaneous SSc. The mean (SD) time since first onset of a non- Raynaud symptom was 3.49 (1.7) years. 49.0% of patients were on stable therapy with mycophenolate at baseline (46.5% mycophenolate mofetil, 1.9% mycophenolate sodium, 0.5% mycophenolic acid). The safety profile in patients with or without mycophenolate at baseline was comparable.</p><p><em><u>Annual rate of decline in FVC</u></em></p><p>The annual rate of decline of FVC (mL) over 52 weeks was significantly reduced by 41.0 mL in patients receiving Ofev compared to patients receiving placebo (Table 10) corresponding to a relative treatment effect of 43.8%.</p><p>&nbsp;</p><p>Table 10:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Annual rate of decline in FVC (mL) over 52 weeks</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev</p><p>150 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Number of analysed patients</p></td><td style="vertical-align:top"><p>288</p></td><td style="vertical-align:top"><p>287</p></td></tr><tr><td style="vertical-align:top"><p>Rate<sup>1</sup> (SE) of decline over 52 weeks</p></td><td style="vertical-align:top"><p>-93.3 (13.5)</p></td><td style="vertical-align:top"><p>-52.4 (13.8)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Comparison vs placebo</p></td></tr><tr><td style="vertical-align:top"><p>Difference<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>41.0</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(2.9, 79.0)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.05</p></td></tr></tbody></table><p><sup>1</sup>Based on a random coefficient regression with fixed categorical effects of treatment, ATA status, gender, fixed continuous effects of time, baseline FVC [mL], age, height, and including treatment-by-time and baseline-by- time interactions. Random effect was included for patient specific intercept and time. Within-patient errors were modelled by an unstructured variance-covariance matrix. Inter-individual variability was modelled by a variance-components variance-covariance matrix.</p><p>&nbsp;</p><p>The effect of Ofev in reducing the annual rate of decline in FVC was similar across pre-specified sensitivity analyses and no heterogeneity was detected in pre-specified subgroups (e.g. by age, gender, and mycophenolate use).</p><p>In addition, similar effects were observed on other lung function endpoints, e.g absolute change from baseline in FVC in mL at week 52 (Figure 5 and Table 11) and rate of decline in FVC in % predicted over 52 weeks (Table 12) providing further substantiation of the effects of Ofev on slowing progression of SSc-ILD. Furthermore, fewer patients in the Ofev group had an absolute FVC decline</p><p>&gt; 5% predicted (20.6% in the Ofev group vs. 28.5% in the placebo group, OR=0.65, p=0.0287). The relative FVC decline in mL &gt; 10% was comparable between both groups (16.7% in the Ofev group vs.</p><p>&nbsp;</p><p>18.1% in the placebo group, OR=0.91, p=0.6842). In these analyses, missing FVC values at week 52 were imputed with the patient&rsquo;s worst value on treatment.</p><p>&nbsp;</p><p>An exploratory analysis of data up to 100 weeks (maximum treatment duration in SENSCIS) suggested that the on treatment effect of Ofev on slowing progression of SSc-ILD persisted beyond 52 weeks.</p><p>&nbsp;</p><p>Figure 5:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean (SEM) observed FVC change from baseline (mL) over 52 weeks</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Image_x0020_7" o:spid="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
  margin-left:78.95pt;margin-top:5.05pt;width:428.4pt;height:327.35pt;
  z-index:-251658237;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image009.png"
   o:title=""/>
  <o:lock v:ext="edit" aspectratio="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="571" height="437" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image010.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>bid = twice daily</p><p>&nbsp;</p><p>Table 11:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Absolute change from baseline in FVC (mL) at week 52</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev</p><p>150 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Number of analysed patients</p></td><td style="vertical-align:top"><p>288</p></td><td style="vertical-align:top"><p>288</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD) at Baseline</p></td><td style="vertical-align:top"><p>2541.0 (815.5)</p></td><td style="vertical-align:top"><p>2458.5 (735.9)</p></td></tr><tr><td style="vertical-align:top"><p>Mean<sup>1</sup> (SE) change from baseline at week 52</p></td><td style="vertical-align:top"><p>-101.0 (13.6)</p></td><td style="vertical-align:top"><p>-54.6 (13.9)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Comparison vs placebo</p></td></tr><tr><td style="vertical-align:top"><p>Mean<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>46.4</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(8.1, 84.7)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.05</p></td></tr></tbody></table><p><sup>1</sup>Based on Mixed Model for Repeated Measures (MMRM), with fixed categorical effects of ATA status, visit, treatment-by-visit interaction, baseline-by-visit interaction age, gender and height. Visit was the repeated measure. Within-patient errors were modelled by unstructured variance-covariance structure. Adjusted mean was based on all analysed patients in the model (not only patients with a baseline and measurement at week 52).</p><p>&nbsp;</p><p>Table 12:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Annual rate of decline in FVC (% predicted) over 52 weeks</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Ofev</p><p>150 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Number of analysed patients</p></td><td style="vertical-align:top"><p>288</p></td><td style="vertical-align:top"><p>287</p></td></tr><tr><td style="vertical-align:top"><p>Rate<sup>1</sup> (SE) of decline over 52 weeks</p></td><td style="vertical-align:top"><p>-2.6 (0.4)</p></td><td style="vertical-align:top"><p>-1.4 (0.4)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Comparison vs placebo</p></td></tr><tr><td style="vertical-align:top"><p>Difference<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.15</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.09, 2.21)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.05</p></td></tr></tbody></table><p><sup>1</sup>Based on a random coefficient regression with fixed categorical effects of treatment, ATA status, fixed continuous effects of time, baseline FVC [% pred], and including treatment-by-time and baseline-by-time interactions. Random effect was included for patient specific intercept and time. Within-patient errors were modelled by an unstructured variance-covariance matrix. Inter-individual variability was modelled by a variance-components variance-covariance matrix</p><p>&nbsp;</p><p><em><u>Change from baseline in Modified Rodnan Skin Score (mRSS) at week 52</u></em></p><p>The adjusted mean absolute change from baseline in mRSS at week 52 was comparable between the Ofev group (-2.17 (95% CI -2.69, -1.65)) and the placebo group (-1.96 (95% CI -2.48, -1.45)). The</p><p>adjusted mean difference between the treatment groups was -0.21 (95% CI -0.94, 0.53; p = 0.5785).</p><p>&nbsp;</p><p><em><u>Change from baseline in St. George&rsquo;s Respiratory Questionnaire (SGRQ) total score at week 52</u> </em>The adjusted mean absolute change from baseline in SGRQ total score at week 52 was comparable between the Ofev group (0.81 (95% CI -0.92, 2.55)) and the placebo group (-0.88 (95% CI -2.58,</p><p>0.82)). The adjusted mean difference between the treatment groups was 1.69 (95% CI -0.73, 4.12;</p><p>p = 0.1711).</p><p>&nbsp;</p><p><em><u>Survival analysis</u></em></p><p>Mortality over the whole trial was comparable between the Ofev group (N = 10; 3.5%) and the placebo group (N = 9; 3.1%). The analysis of time to death over the whole trial resulted in a HR of</p><p>1.16 (95% CI 0.47, 2.84; p = 0.7535).</p><p><u>QT interval</u></p><p>In a dedicated study in renal cell cancer patients, QT/QTc measurements were recorded and showed that a single oral dose of 200 mg nintedanib as well as multiple oral doses of 200 mg nintedanib administered twice daily for 15 days did not prolong the QTcF interval.</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Ofev in all subsets of the paediatric population in IPF (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Nintedanib reached maximum plasma concentrations approximately 2 - 4 h after oral administration as soft gelatine capsule under fed conditions (range 0.5 - 8 h). The absolute bioavailability of a 100 mg dose was 4.69% (90% CI: 3.615 - 6.078) in healthy volunteers. Absorption and bioavailability are decreased by transporter effects and substantial first-pass metabolism. Nintedanib exposure increased dose-proportionally in the dose range of 50-450 mg once daily and 150-300 mg twice daily. Steady state plasma concentrations were achieved within one week of dosing at the latest.</p><p>&nbsp;</p><p>After food intake, nintedanib exposure increased by approximately 20% compared to administration under fasted conditions (CI: 95.3 - 152.5%) and absorption was delayed (median tmax fasted: 2.00 h; fed: 3.98 h).</p><p><br />Distribution<br />Nintedanib follows at least bi-phasic disposition kinetics. After intravenous infusion, a high volume of<br />distribution (Vss: 1,050 L, 45.0% gCV) was observed.<br />The in vitro protein binding of nintedanib in human plasma was high, with a bound fraction of 97.8%.<br />Serum albumin is considered to be the major binding protein. Nintedanib is preferentially distributed<br />in plasma with a blood to plasma ratio of 0.869.<br />Biotransformation<br />The prevalent metabolic reaction for nintedanib is hydrolytic cleavage by esterases resulting in the free<br />acid moiety BIBF 1202. BIBF 1202 is subsequently glucuronidated by uridine 5&#39;-diphosphoglucuronosyltransferase<br />enzymes (UGT) enzymes, namely UGT 1A1, UGT 1A7, UGT 1A8, and<br />UGT 1A10 to BIBF 1202 glucuronide.<br />Only a minor extent of the biotransformation of nintedanib consisted of CYP pathways, with<br />CYP 3A4 being the predominant enzyme involved. The major CYP-dependent metabolite could not be<br />detected in plasma in the human ADME study. In vitro, CYP-dependent metabolism accounted for<br />about 5% compared to about 25% ester cleavage. Nintedanib, BIBF 1202, and BIBF 1202 glucuronide<br />did not inhibit or induce CYP enzymes in preclinical studies, either. Drug-drug interactions between<br />nintedanib and CYP substrates, CYP inhibitors, or CYP inducers are therefore not expected.<br />Elimination<br />Total plasma clearance after intravenous infusion was high (CL: 1,390 mL/min, 28.8% gCV). Urinary<br />excretion of the unchanged active substance within 48 h was about 0.05% of the dose (31.5% gCV)<br />after oral and about 1.4% of the dose (24.2% gCV) after intravenous administration; the renal<br />clearance was 20 mL/min (32.6% gCV). The major route of elimination of drug related radioactivity<br />after oral administration of [14C] nintedanib was via faecal/biliary excretion (93.4% of dose,<br />2.61% gCV). The contribution of renal excretion to the total clearance was low (0.649% of dose,<br />26.3% gCV). The overall recovery was considered complete (above 90%) within 4 days after dosing.<br />The terminal half-life of nintedanib was between 10 and 15 h (gCV % approximately 50%).<br />Linearity/non-linearity<br />The pharmacokinetics (PK) of nintedanib can be considered linear with respect to time (i.e. singledose<br />data can be extrapolated to multiple-dose data). Accumulation upon multiple administrations was<br />1.04-fold for Cmax and 1.38-fold for AUC&tau;. Nintedanib trough concentrations remained stable for more<br />than one year.<br />Transport<br />Nintedanib is a substrate of P-gp. For the interaction potential of nintedanib with this transporter, see<br />section 4.5. Nintedanib was shown to be not a substrate or inhibitor of OATP-1B1, OATP-1B3,<br />OATP-2B1, OCT-2, or MRP-2 in vitro. Nintedanib was also not a substrate of BCRP. Only a weak<br />inhibitory potential on OCT-1, BCRP, and P-gp was observed in vitro which is considered to be of<br />low clinical relevance. The same applies for nintedanib being a substrate of OCT-1.<br />Population pharmocokinetic analysis in special populations<br />The PK properties of nintedanib were similar in healthy volunteers, patients with IPF, patients with<br />other chronic fibrosing ILDs with a progressive phenotype, patients with SSc-ILD, and cancer<br />patients. Based on results of a population PK (PopPK) analysis in patients with IPF and non small cell<br />lung cancer (NSCLC) (N=1,191) and descriptive investigations, exposure to nintedanib was not<br />influenced by sex (body weight corrected), mild and moderate renal impairment (estimated by<br />creatinine clearance), alcohol consumption, or P-gp genotype.<br />PopPK analyses indicated moderate effects on exposure to nintedanib depending on age, body weight,<br />and race (see below). Based on the high inter-individual variability of exposure observed moderate<br />effects are considered not clinically relevant (see section 4.4).<br />26<br />Age<br />Exposure to nintedanib increased linearly with age. AUC&tau;,ss decreased by 16% for a 45-year old patient<br />and increased by 13% for a 76-year old patient relative to a patient with the median age of 62 years.<br />The age range covered by the analysis was 29 to 85 years; approximately 5% of the population were<br />older than 75 years. Based on a PopPK model, an increase in nintedanib exposure of approximately<br />20 - 25% was observed in patients &ge; 75 years compared with patients under 65 years.<br />Body weight<br />An inverse correlation between body weight and exposure to nintedanib was observed. AUC&tau;,ss<br />increased by 25% for a 50 kg patient (5th percentile) and decreased by 19% for a 100 kg patient<br />(95th percentile) relative to a patient with the median weight of 71.5 kg.<br />Race<br />The population mean exposure to nintedanib was 33 - 50% higher in Chinese, Taiwanese, and Indian<br />patients and 16% higher in Japanese patients while it was 16 - 22% lower in Koreans compared to<br />Caucasians (body weight corrected). Data from Black individuals were very limited but in the same<br />range as for Caucasians.<br />Hepatic impairment<br />In a dedicated single dose phase I study and compared to healthy subjects, exposure to nintedanib<br />based on Cmax and AUC was 2.2-fold higher in volunteers with mild hepatic impairment (Child<br />Pugh A; 90% CI 1.3 &ndash; 3.7 for Cmax and 1.2 &ndash; 3.8 for AUC, respectively). In volunteers with moderate<br />hepatic impairment (Child Pugh B), exposure was 7.6-fold higher based on Cmax (90% CI 4.4 &ndash; 13.2)<br />and 8.7-fold higher (90% CI 5.7 &ndash; 13.1) based on AUC, respectively, compared to healthy volunteers.<br />Subjects with severe hepatic impairment (Child Pugh C) have not been studied.<br />Concomitant treatment with pirfenidone<br />In a dedicated pharmacokinetic study, concomitant treatment of nintedanib with pirfenidone was<br />investigated in patients with IPF. Group 1 received a single dose of 150 mg nintedanib before and after<br />uptitration to 801 mg pirfenidone three times a day at steady state (N=20 patients treated). Group 2<br />received steady state treatment of 801 mg pirfenidone three times a day and had a PK profiling before<br />and after at least 7 days of co-treatment with 150 mg nintedanib twice daily (N=17 patients treated). In<br />group 1, the adjusted geometric mean ratios (90% confidence interval (CI)) were 93% (57% - 151%)<br />and 96% (70% - 131%) for Cmax and AUC0-tz of nintedanib, respectively (n=12 for intraindividual<br />comparison). In group 2, the adjusted geometric mean ratios (90% CI)) were 97% (86% - 110%) and<br />95% (86% - 106%) for Cmax,ss and AUC&tau;,ss of pirfenidone, respectively (n=12 for intraindividual<br />comparison).<br />Based on these results, there is no evidence of a relevant pharmacokinetic drug-drug interaction<br />between nintedanib and pirfenidone when administered in combination (see section 4.4).<br />Concomitant treatment with bosentan<br />In a dedicated pharmacokinetic study, concomitant treatment of Ofev with bosentan was investigated<br />in healthy volunteers. Subjects received a single dose of 150 mg Ofev before and after multiple dosing<br />of 125 mg bosentan twice daily at steady state. The adjusted geometric mean ratios (90% confidence<br />interval (CI)) were 103% (86% - 124%) and 99% (91% - 107%) for Cmax and AUC0-tz of nintedanib,<br />respectively (n=13), indicating that co-administration of nintedanib with bosentan did not alter the<br />pharmacokinetics of nintedanib.<br />Concomitant treatment with oral hormonal contraceptives<br />In a dedicated pharmacokinetic study, female patients with SSc-ILD received a single dose of a<br />combination of 30 &mu;g ethinylestradiol and 150 &mu;g levonorgestrel before and after twice daily dosing of<br />150 mg nintedanib for at least 10 days. The adjusted geometric mean ratios (90% confidence interval<br />(CI)) were 117% (108% - 127%; Cmax) and 101% (93% - 111%; AUC0&ndash;tz) for ethinylestradiol and<br />101% (90% - 113%; Cmax) and 96% (91% - 102%; AUC0&ndash;tz) for levonorgestrel, respectively (n=15),<br />27<br />indicating that co-administration of nintedanib has no relevant effect on the plasma exposure of<br />ethinylestradiol and levonorgestrel.<br />Exposure-response relationship<br />Exposure-response analyses of patients with IPF and other chronic fibrosing ILDs with a progressive<br />phenotype, indicated a weak relationship between nintedanib plasma exposure and ALT and/or AST<br />elevations. Actual administered dose might be the better predictor for the risk of developing diarrhoea<br />of any intensity, even if plasma exposure as risk determining factor could not be ruled out (see section<br />4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General toxicology<br />In repeat dose toxicology studies in young rats, irreversible changes of enamel and dentin were observed in the continuously fast-growing incisors, but not in premolars or molars. In addition, thickening of epiphyseal growth plates during bone growth phases was observed and was reversible after discontinuation.<br />Reproduction toxicity<br />In rats, embryo-foetal lethality and teratogenic effects were observed at exposure levels below human<br />exposure at the MRHD of 150 mg twice daily. Effects on the development of the axial skeleton and on<br />the development of the great arteries were also noted at subtherapeutic exposure levels.<br />In rabbits, embryo-foetal lethality and teratogenic effects were observed at an exposure approximately<br />3 times higher than at the MRHD but equivocal effects on the embryo-foetal development of the axial<br />skeleton and the heart were noted already at an exposure below that at the MRHD of 150 mg twice<br />daily.<br />In a pre- and postnatal development study in rats, effects on pre- and post-natal development were<br />seen at an exposure below the MRHD.<br />A study of male fertility and early embryonic development up to implantation in rats did not reveal<br />effects on the male reproductive tract and male fertility.<br />In rats, small amounts of radiolabelled nintedanib and/or its metabolites were excreted into the milk<br />(&le; 0.5% of the administered dose).<br />From the 2-year carcinogenicity studies in mice and rats, there was no evidence for a carcinogenic<br />potential of nintedanib.<br />Genotoxicity studies indicated no mutagenic potential for nintedanib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content</u></p><p>triglycerides, medium-chain hard fat</p><p>lecithin (soya) (E322)</p><p>&nbsp;</p><p><u>Capsule shell</u></p><p>gelatin glycerol (85%)</p><p>titanium dioxide (E171) iron oxide red (E172) iron oxide yellow (E172)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2 - 8&deg;C).</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ofev 100 mg soft capsules<br />Ofev 100 mg soft capsules are available in the following pack-sizes:<br />- 30 x 1 soft capsules in aluminium/aluminium perforated unit dose blisters<br />- 60 x 1 soft capsules in aluminium/aluminium perforated unit dose blisters<br />Ofev 150 mg soft capsules<br />Ofev 150 mg soft capsules are available in the following pack-sizes:<br />- 30 x 1 soft capsules in aluminium/aluminium perforated unit dose blisters<br />- 60 x 1 soft capsules in aluminium/aluminium perforated unit dose blisters<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of coming in contact with the content of the capsule, hands should be washed off<br />immediately with plenty of water (see section 4.2).<br />Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>